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Abstract	  	  	   TITLE:	  MYCOPLASMA	  ARGININI	  INCREASES	  ACTIVATION,	  ENERGETIC	  DEREGULATION,	  AND	  TUMOR	  PROGRESSION	  OF	  VM-­‐M3	  METASTATIC	  MACROPHAGE	  CELLS.	  	  AUTHOR:	  ROBERTO	  ETTORE	  FLORES	  	  Thesis	  Advisor:	  Thomas	  N.	  Seyfried,	  Ph.D.	  	  	  Mycoplasmas	   are	   the	   smallest,	   self-­‐replicating	   free-­‐living	   prokaryotes,	   and	   have	  been	   associated	   with	   carcinogenesis.	  	   Mycoplasmas	   can	   be	   detected	   in	   a	   high	  percentage	  of	  a	  wide	  variety	  of	  primary	  human	  cancers.	  	  Some	  mycoplasma	  species	  such	   as	  M.	   fermentans	  and	  M.	   hyorhinis	  can	   transform	   normal	   murine	   and	   human	  cell	   lines	   into	   tumorigenic	   cells.	  	   Mycoplasma	   infection	   can	   activate	   oncogenes	   as	  well	   as	   inactivate	   tumor	   suppressor	   genes.	  	   These	   observations	   suggest	   that	  mycoplasmas	   can	   be	   both	   carcinogenic	   and	   or	   onco-­‐modulatory.	   	  I	   found	   that	   the	  metastatic	   macrophage	   VM-­‐M3	   cell	   line	   (referred	   to	   as	   M3+)	   was	   infected	   with	  mycoplasmas.	  	  Mycoplasmal16S	  rDNA	  sequencing	  showed	  M3+	  cells	  were	   infected	  by	  the	  mycoplasma	  species	  M.	  arginini.	  	  Antibiotic	  was	  used	  to	  eradicate	  M.	  arginini	  from	  M3+	  cells	  (referred	  to	  as	  M3-­‐	  cells).	   	  The	  energetics	  of	  the	  infected	  M3+	  cells	  and	   the	   non-­‐infected	   M3-­‐	   cells	   was	   studied	   by	   measuring	   respiration	   (oxygen	  consumption)	   and	   fermentation	   (lactate	   production).	   	   Respiration	   was	   enhanced	  and	  fermentation	  was	  reduced	  in	  the	  M3-­‐	  cells	  compared	  to	  the	  M3+	  cells.	  	  Glucose	  enhanced	   the	   fermentation	   and	   reduced	   the	   respiration	   of	   both	   the	  M3+	   and	   the	  M3-­‐	   cells.	   	   The	  M3+	   cells	   produced	   higher	   quantities	   of	   metabolites	   indicative	   of	  
immunological	  activation	  (itaconic	  acid,	  succinate,	  and	  citrulline)	  compared	  to	  M3-­‐	  cells.	  	  In	  addition,	  in-­‐vitro	  proliferation	  was	  higher	  in	  the	  M3+	  cells	  than	  in	  the	  M3-­‐	  cells	  at	  high	  cell	  densities.	  	  Primary	  subcutaneous	  tumor	  growth	  and	  metastasis	  was	  less	  in	  mice	  inoculated	  with	  the	  M3-­‐	  cells	  than	  with	  the	  M3+	  cells.	  	  The	  survival	  of	  a	  VM	  mouse	  was	   longer	   when	   inoculated	  with	   the	  M3-­‐	   cells	   compared	   to	   the	  M3+	  cells.	   	   Altogether	   these	   data	   indicates	   that	  M.	   arginini	   is	   an	   onco-­‐modulator	  associated	  with	  activation,	  deregulated	  energetics	  and	  enhanced	  tumor	  progression	  	  of	  VM-­‐M3	  metastatic	  macrophage	  cells.
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Introduction	  Mycoplasmas	   of	   the	   Mollicutes	   class	   are	   considered	   the	   smallest	   self-­‐replicating	  free-­‐living	   prokaryotes	   (1).	   	   Mycoplasma	   16S	   rRNA	   sequencing	   data	   used	   as	   a	  phylogenetic	   measure	   suggests	   that	   mycoplasmas	   originated	   from	   walled	   gram-­‐positive	   eubacteria	   by	   degenerative	   evolution	   roughly	   600	   million	   years	   ago	   (2).	  Unlike	   their	  walled	  ancestors,	   the	  Mollicutes	   (soft	   skin)	   class	   lacks	  a	   cell	  wall	   and	  thus	  is	  resistant	  to	  common	  bacterial	  cell	  wall	  targeted	  antibiotics	  such	  as	  penicillin.	  Mycoplasmas	  range	  in	  size	  from	  0.3µm	  to	  0.8µm,	  which	  in	  turn	  reflects	  their	  small	  genome	  sizes.	  	  	  M.	  genitalium	  has	  the	  smallest	  genome	  (580	  kb)	  of	  any	  organism	  that	  can	   be	   grown	   in	   pure	   culture	   and	   M.	   hyorhinis	   has	   the	   largest	   genome	   of	   the	  mycoplasmas	   (820	   kb)	   (3)	   (2)	   (4).	  With	   limited	   coding	   capacity,	   the	  mycoplasma	  genus	   has	   stringent	   nutritional	   requirements	   for	   fatty	   acids,	   sterols,	   some	   amino	  acids,	   nucleic	   acids,	   and	   various	   vitamins/cofactors	   (4)	   (5).	   	   Dependence	   on	  metabolic	  precursors	  for	  life	  leads	  to	  the	  need	  of	  extremely	  complex	  media	  in	  order	  to	  cultivate	  and	  therefore	  study	  mycoplasmas.	  	  However,	  high	  mycoplasma	  infection	  rates	  show	  that	  mycoplasmas	  propagate	  well	  within	  or	  attached	  to	  mammalian	  cells	  in-­‐vitro	  (6)	  (1).	  	  	  	  Mycoplasma	  infection	  of	  cultured	  mammalian	  cells	  can	   falsify	  many	  metabolic	  and	  non-­‐metabolic	  cellular	  assays	  including	  oxygen	  consumption	  assays	  (7),	  nitric	  oxide	  synthase	  activity	  (8),	  MTT	  viability	  assays	  (9),	  and	  mitochondrial	  protein	  synthesis	  determination	   (mycoplasma	   co-­‐purified	  with	   the	  mitochondrial	   fraction)	   (10).	   	   In	  agreement,	  M.	  hominis	  infection	  of	  HeLa	  cells	  significantly	  altered	  genetic	  expression	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profiles	   of	   1972	   genes	   (11).	   	   Another	   study	   found	   approximately	   200	   significant	  expression	   profile	   alterations	   in	   infected	  MCF7	   cells	   and	   70	   of	   those	   genes	   were	  involved	   in	   metabolism	   (12).	   In	   Mycoplasma	   pneumoniae-­‐infected	   individuals,	  tracheal	   cell	   explants	   were	   shown	   to	   have	   a	   decrease	   in	   ATP	   from	   respiration,	  possibly	   due	   to	   lower	   dehydrogenase	   activities	   of	   the	   cells	   (10).	   	   Similarly,	   M.	  hyorhinis	  is	  also	  capable	  of	  reducing	  the	  respiration	  system	  in	  heavily	  contaminated	  human	   skin	   fibroblast	   cells	   (13).	   	   Thus,	   mycoplasmas	   have	   a	   high	   potential	   for	  modulating	  host	  metabolism.	  	  	  
	  Regarding	   energy	   catabolism,	   mycoplasmas	   can	   be	   classified	   as	   fermentative	   or	  non-­‐fermentative	   (14).	   	   Fermentative	   mycoplasmas	   are	   able	   to	   gain	   energy	   by	  substrate-­‐level	   phosphorylation	   of	   ADP	   by	   glycolysis,	   specifically	   by	   the	   Embden-­‐Meyerhof-­‐Parnas	  (EMP)	  Pathway	  (14).	  	  Fermentation	  produces	  acid	  and	  occurs	  not	  to	   specifically	   make	   energy,	   but	   rather	   to	   oxidize	   NADH	   to	   allow	   glycolysis	   to	  continue	   to	   make	   energy	   (NAD+	   is	   required	   for	   the	   6th	   step	   of	   glycolysis)	   (15).	  	  	  Therefore,	   fermentative	   mycoplasmas	   are	   acidifiers	   and	   thus	   reducers	   of	   their	  environment.	   Some	   fermentative	   mycoplasmas	   such	   as	  M.	   gallisepticum	   have	   the	  ability	  to	  carry	  out	  a	  non-­‐fermentative	  catabolism	  (16)	  (17)	  but	  viability	  and	  growth	  during	   a	   non-­‐fermentative	   catabolism	   are	   unclear.	   	   	   However	   in	   the	   presence	   of	  glucose,	   fermentative	  mycoplasmas	  produce	  a	  net	  waste	  of	  acid.	   In	  contrast,	  non-­‐fermentative	   mycoplasmas	   do	   not	   produce	   a	   net	   waste	   of	   acid	   or	   alcohol,	   which	  indicates	   that	   their	   energy	   catabolism	   is	   mainly	   oxidative.	   In	   part,	   the	   oxidative	  catabolism	   of	   the	   non-­‐fermentative	   mycoplasmas	   is	   perhaps	   due	   to	   the	   lack	   of	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phosphofructokinase	  and	  aldolase	  activity	  of	   the	  EMP	  pathway	   in	  these	  organisms	  (14).	   	   Thus,	   respiration	   (oxidation)	   rather	   than	   fermentation	   (reduction)	  characterizes	  the	  non-­‐fermentative	  mycoplasmas.	  	  	  	  Even	   though	   non-­‐fermentative	   species	   of	   mycoplasma	   seem	   unable	   to	   ferment	  glucose,	   they	   possibly	   generate	   energy	   anaerobically	   through	   the	   arginine	  dihydrolase	  pathway	   (18).	   	  However,	   the	   aerobic	  or	   anaerobic	   contribution	  of	   the	  arginine	   dihydrolase	   pathway	   to	   overall	   energy	   generation	   in	   any	   one	   species	   is	  unclear.	   	   	  Some	  non-­‐fermentative	  mycoplasma	  species	  require	  arginine	  for	  growth,	  while	   other	   species	   can	   grow	   without	   arginine.	   	   For	   example,	   only	   one	   of	   three	  strains	  of	  M.	  arginini	  was	  found	  to	  require	  arginine	  for	  growth	  (19).	  	  M.	  arginini	  was	  named	   as	   so	   simply	   because	   the	   author	   discovered	   that	   arginine	   boosted	   growth,	  rather	  than	  glucose	  or	  urea.	  (20).	  	  Whether	  arginine	  is	  utilized	  by	  non-­‐fermentative	  mycoplasmas	  more	  for	  catabolic	  or	  anabolic	  needs	  is	  unclear	  (21)	  (19)	  (22).	   	  Since	  
M.	  arginini	  contains	  a	  flavin-­‐terminated	  respiratory	  chain	  it	  is	  likely	  that	  M.	  arginini	  uses	  both	  respiration	  and	  the	  arginine	  dihydrolase	  pathway	  for	  energy	  production	  according	  to	  oxygen	   levels	  and	  metabolic	   fuel	  supply	  set	  by	   the	  environment	  (19).	  	  In	   hypoxic	   conditions	   that	   may	   not	   allow	   for	   sufficient	   energy	   generation	   from	  respiration,	   arginine-­‐utlizing	   mycoplasma	   would	   most	   likely	   generate	   energy	  through	   the	   anaerobic	   arginine	   dihydrolase	   system,	   just	   as	   the	   fermentative	  mycoplasmas	  would	  generate	  energy	  through	  anaerobic	  lactate	  fermentation.	  	  	  	  Even	  though	  the	  interaction	  between	  host	  and	  mycoplasma	  is	  typically	  commensal,	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mycoplasmas	   are	   well	   known	   for	   their	   parasitic	   nature	   (23),	   partly	   due	   to	   their	  fastidious	  metabolic	   needs	   (4)	   and	   partly	   due	   to	   their	   ability	   to	   promote	   chronic	  inflammation	  (24).	   	  Various	  strains	  of	  mycoplasmas	  are	  capable	  of	  causing	  disease	  as	  well	  as	  implicated	  as	  co-­‐factors	  in	  dozens	  of	  others,	  but	  their	  virulent	  capabilities	  and	  potential	   are	   just	  beginning	   to	  unfold	   (25)	   (26)	   (27)	   (23)	   (24).	   Irrespective	  of	  the	   role	  mycoplasmas	   play	   in	   disease	   as	   benign	   colonist,	   co-­‐contributors,	   or	   even	  the	   cause,	   they	   have	   a	   robust	   ability	   to	   modulate	   inflammation,	   metabolism,	   and	  cancer.	  	  A	   search	   for	   the	   link	   between	   mycoplasmas	   and	   cancer	   began	   after	   some	  mycoplasma	  species	  were	  shown	  to	  be	  sufficient	  in	  causing	  non-­‐tumorigenic	  cells	  to	  transform	   into	   tumorigenic	   cells	   (28)	   (29).	   	   In	   addition	   to	   the	   classic	  hallmarks	  of	  cancer,	   an	   emerging	   hallmark	   is	   deregulated	   energetics	   (30).	   	   As	   detailed	   above,	  mycoplasmas	  seem	  sufficient	  in	  deregulating	  cellular	  energetics.	  Also,	  mycoplasmas	  have	  been	  shown	  to	  induce	  cells	  to	  evade	  apoptosis	  (31)	  (32),	  sustain	  proliferation	  (24)	   (5),	   enable	   replicative	   immortality	   (33),	   and	  activate	   invasion	  and	  metastasis	  (34)	   (35),	   which	   are	   all	   four	   classic	   hallmarks	   of	   cancer	   (30).	   	   Alongside	   the	  deregulating	  of	  cellular	  energetics,	  the	  other	  emerging	  hallmark	  of	  cancer	  cells	  is	  the	  ability	   to	   avoid	   immune	   destruction.	   	   Recently,	   mycoplasma	   infected	   tumor	   cells	  were	  found	  to	  release	  exosomes	  that	  activate	  inhibitory	  B-­‐cells,	  which	  in	  turn	  inhibit	  T	  cells	  cytotoxic	  to	  cancer	  cells	  (36).	  Interestingly,	  mycoplasmas	  also	  cause	  genomic	  instability	   (37)	   (38)	   and	   inflammation	   (39)	   (40),	   both	  major	  hallmark-­‐enabling	  
characteristics	   of	   neoplasia.	   	   In	   addition,	   mycoplasma	   infection	   is	   strongly	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associated	  with	  onco-­‐genetic	  alterations.	  During	  transformation	  of	  non-­‐tumorigenic	  C3H	   mouse	   embryo	   cells	   into	   tumorigenic	   cells,	  M.	   fermentans	   and	  M.	   penetrans	  have	  been	  shown	  to	  cause	  constitutive	  H-­‐ras	  and	  c-­‐myc	  expression	  (41).	  	  Moreover,	  
M.	  arginini	  infection	  has	  been	  shown	  to	  cooperate	  with	  oncogenic	  Ras,	  activate	  NF-­‐kB,	   and	   suppress	   p53	   (32).	   	   All	   mycoplasma	   species	   tested	   by	   these	   authors	  suppressed	   p53,	   but	  M.	   arginini	   showed	   the	   greatest	   ability	   to	   suppress	   p53.	   	   In	  addition	   to	   mycoplasma	   infection	   being	   strongly	   linked	   to	   the	   hallmarks	   and	  characteristics	   of	   cancer,	   their	   presence	   in	   a	   variety	   of	   human	   primary	   tumor	  samples	   strengthens	   the	  possibility	  of	   a	   causative	  or	  at	   least	   a	  modulatory	   role	   in	  human	  carcinogenesis	  (28)	  (42)	  (43)	  (44)	  (45).	  	  The	  ability	  of	  mycoplasmas	  to	  cause	  chronic	   inflammation	   and	   activate	   NF-­‐kB	   further	   strengthens	   the	   link	   between	  mycoplasma,	  inflammation	  and	  cancer.	  	  Although	  some	   immune	  cells	  can	  help	  eradicate	   tumor	  cells,	   inflammation	  created	  by	   tumor-­‐associated	   immune	   cells	   ultimately	   balances	   out	   towards	   that	   of	   tumor	  promotion	   rather	   than	   of	   regression	   (46).	   	   In	   agreement	  with	   the	   surprising	   and	  counterintuitive	  findings	  that	  immune	  cells	  ultimately	  promote	  tumor	  progression,	  tumor-­‐associated	  immune	  cells	  have	  been	  found	  to	  enable	  some	  of	  the	  hallmarks	  of	  cancer	   (30).	  Many	   types	   of	   immune	   cells	   are	   able	   to	   promote	   tumor	   progression,	  including	   T	   lymphocytes,	   B	   lymphocytes,	   and	   macrophage	   subtypes	   (47)	   (48).	  	  Typically,	  type	  M2	  macrophages	  are	  thought	  to	  stimulate	  cancer	  progression	  while	  type	  M1	  macrophages	  have	  been	  shown	  to	  be	  important	  for	  tumor	  regression	  (48).	  	  	  However,	  Egeblad	  et	  al.	  suggest	  that	  tumor-­‐associated	  macrophages	  (TAM)	  may	  be	  a	  
	   6	  
continuum	   of	   various	  M1	   and	  M2	   subtypes	   rather	   than	   rigidly	   being	   classified	   as	  solely	  M1	  or	  M2	  (49).	  	  Regardless	  of	  the	  exact	  type	  of	  macrophage,	  the	  transcription	  factor	  Hypoxia	  Inducible	  Factor	  1-­‐alpha	  (HIF-­‐1α)	  has	  been	  described	  to	  be	  a	  master	  regulator	   for	   tumor	   promoting	   TAM	   (50).	   	   The	   HIF-­‐1α	   expression	   of	   TAM	   links	  tumor-­‐promoting	  inflammation	  and	  deregulated	  cellular	  energetics,	  i.e.	  a	  hallmark-­‐enabling	  characteristic	  of	  cancer	  with	  an	  emerging	  hallmark	  of	  cancer,	  respectively	  (51).	  Tumor-­‐promoting	   inflammation	   is	   referred	   to	   as	   “smoldering”	  because	  of	   its	  chronic	   and	   low-­‐grade	   nature	   (52).	   	   Interestingly,	   mycoplasma-­‐induced	  inflammation	  seems	  to	  recapitulate	  tumor-­‐promoting	  inflammation	  as	  both	  are	  NF-­‐
KB-­‐driven,	   chronic	   and	   low-­‐grade	   in	   nature	   (53).	   	   The	   link	   between	   infection,	  chronic	  inflammation,	  and	  cancer	  has	  been	  noted	  (54).	  	  My	   study	   investigates	   the	  metabolic	   and	   tumorigenic	   consequences	   of	  M.	  arginini	  infection	  in	  metastatic	  murine	  macrophage	  tumor	  cells	  (VM-­‐M3	  cells).	   	  The	  VM-­‐M3	  tumor	  arose	  spontaneously	  in	  the	  cerebrum	  of	  a	  male	  adult	  VM/Dk	  mouse.	  The	  VM-­‐M3	   cells	   (M3)	   are	  more	   specifically	   characterized	   as	  microglia	   since	   they	   express	  morphological,	  behavior,	  biochemical,	  and	  genetic	  properties	  of	  macrophages	  (55).	  When	   inoculated	   in	   the	   syngeneic	  VM	  mouse	  host,	  M3	   cells	   recapitulate	   all	  major	  biological	  processes	  of	  metastasis	   to	   include	   local	   invasion,	   intravasation,	   immune	  system	   survival,	   extravasation	   and	   secondary	   tumor	   formation	   involving	   liver,	  kidney,	  spleen,	  lung	  and	  brain	  (55).	  	  Inoculation	  of	  M3	  directly	  into	  the	  brain	  seems	  to	  biologically	  mimic	  the	  characteristics	  of	  glioblastoma	  seen	  in	  the	  human	  (56).	  	  In	  the	   present	   study	   the	   M3	   cells	   were	   diagnosed	   with	   an	   M.	   arginini	   infection,	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however	   the	   origin	   or	   date	   of	   the	   infection	   is	   unclear.	   	   After	   eradication	   of	   M.	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Materials	  and	  Methods	  
	  
Cell	  lines	  and	  culture	  conditions	  	  The	   VM-­‐M3+	   cell	   line	   was	   established	   from	   flank-­‐grown	   VM	   cerebral	   tumors	   as	  previously	   described	   (55).	   	   VM-­‐M3	   (M3)	   cells	  were	   grown	   in	  Dulbecco’s	  modified	  Eagle	   medium	   (DMEM,	   Sigma,	   St.	   Louis,	   MO)	   with	   high	   glucose	   (25	   mM)	  supplemented	  with	  10%	   fetal	  bovine	  serum	  (FBS,	  Sigma)	  and	  50	   lg/ml	  penicillin–streptomycin	  (Sigma).	  M3	  cells	  were	  cultured	  in	  a	  CO2	  incubator	  with	  a	  humidified	  atmosphere	  containing	  95%	  air	  and	  5%	  CO2	  at	  37C.	   	  The	  M3	  cells	  were	  passaged	  approximately	  one	  time	  per	  week	  or	  when	  80%	  confluency	  was	  reached.	  The	  M3II	  cells	  (clone	  II)	  were	  treated	  exactly	  as	  the	  M3	  cells.	  	  
Eradication	  and	  Identification	  of	  Mycoplasma	  VM-­‐M3	  cells	  were	  eradicated	  by	  adding	  MycoZap	  (Lonza)	   to	   the	  culture	  media	   for	  one	  week,	  with	  the	  starting	  point	  being	  right	  after	  cells	  plated	  down	  to	  the	  culture	  plastic	   at	   low	   density	   (100,000	   cells/100mm	   dish).	   	   In	   a	   separate	   incubator	   a	  control	  dish	  of	  VM-­‐M3	  cells	  with	  no	  mycoplasmal	   targeted	  antibiotics	  was	   treated	  and	  passaged	  in	  conjunction	  with	  the	  MycoZap	  treated	  dish	  at	  all	  times.	  	  The	  media	  was	  changed	  every	  48	  hours	  and	  no	  change	   in	  growth	  or	  cell	  death	  was	  noted.	   	  A	  subsequent	   treatment	   of	   ciprofloxacin	   (10ug/mL)	   was	   used	   for	   one	   week	   as	   a	  prophylactic	  strategy	  exactly	  as	  described	   for	  MycoZap	  above.	   	   	  After	  one	  week	  of	  ciprofloxacin	  prophylactic	  treatment	  the	  VM-­‐M3	  cells	  were	  grown	  for	  an	  additional	  week	   only	   with	   the	   usual	   Penicillin/streptomycin	   antibiotics,	   which	   were	   not	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removed	   during	   MycoZap/Ciprofloxacin	   treatments.	   	   Treated	   VM-­‐M3	   cells	   and	  untreated	  VM-­‐M3	  cells	  were	  subjected	  to	  a	  MycoAlert	  Detection	  Assay	  and	  e-­‐myco	  Plus	   PCR	   detection	   (Bulldog	   Bio)(Figure	   1)	   to	   verify	   eradication	   of	   infection.	  	  Identification	   of	  M.	  arginini	   infection	  was	   done	   by	   excision	   and	   sequencing	   of	   the	  positive	  260	  bp	  16S	  rDNA	  band	  in	  an	  e	  -­‐Myco	  plus	  Mycoplasma	  PCR	  Detection	  Kit	  1.5%	   agarose	   gel.	   	   The	   mycoplasmal	   16S	   rDNA	   sequence	   (query)	   was	   BLAST	  searched	  against	   the	  GenBank	  database	   and	   the	  best	  match	   (subject)	  or	   top	   score	  was	  Mycoplasma	  arginini.	  	  	  	  
Oxygen	   consumption	   and	   Extracellular	   Acification	   Rate,	   and	   Lactate	  
Measurements	  Oxygen	  consumption	  rate	  and	  Extracellular	  acidification	  rate	  (ECAR)	  was	  taken	  with	  a	   Seahorse	   XF96	   Extracellular	   Flux	   Analzyer.	   	   M3+	   or	   M3-­‐	   cells	   were	   seeded	   at	  30,000	  cells	  per	  XF96	  plate	  well	  and	  allowed	  to	  incubate	  for	  12	  hours	  in	  DMEM	  high	  glucose	  with	   10%	   FBS.	   	   The	  media	  was	   then	   changed	   to	   complete	  media	  with	   or	  without	  100	  nM	  Antimycin	  A	  (complete	  media:	  DMEM	  with	  2	  mM	  glutamine,	  10mM	  glucose,	  and	  0.5	  mg/mL	  Albumax	  I.	  	  No	  FBS	  and	  no	  bicarbonate	  were	  included	  in	  the	  media	  as	  recommended	  by	  Seahorse	  for	  ECAR	  measurements.	   	  Phenol	  red	  was	  not	  included	   since	   visual	   pH	   monitoring	   was	   unnecessary.	   	   The	   Crabtree	   effect	   was	  circumvented	  by	  simply	  not	  including	  glucose	  in	  complete	  media).	  	  Two	  hours	  later	  the	  media	  was	  changed	  again	  to	  complete	  media	  and	  the	  plate	  was	  quickly	  inserted	  into	   the	   XF96	   analyzer.	   	   The	   XF96	   analyzer	   was	   programmed	   to	   take	   7	   minute	  measurements	  with	  a	  1-­‐minute	  mix	  and	  a	  1-­‐minute	  wait	  period	  before	  a	  subsequent	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7	  minutes	  measurement	  was	  taken.	   	  The	  total	  measurement	  time	  was	  2	  hours	  and	  the	  average	  O2	  consumption	  was	  calculated.	  	  O2	  consumption	  rate	  and	  ECAR	  were	  steady	  throughout	  the	  2	  hour	  time	  period.	  	  	  	  Lactate	  production	  rate	  was	  assessed	  by	  collection	  of	  the	  media	  of	  each	  XF	  analyzer	  96-­‐well	   with	   a	   subsequent	   Eton	   Bioscience’s	   L-­‐lactate	   assay	   I	   kit.	   	   Taking	   the	  millimoles	   of	   lactate	   and	   multiplying	   by	   the	   total	   microliters	   in	   each	   well	  determined	   the	   total	   millimoles	   of	   lactate.	   The	   total	   O2	   consumption	   rate,	   ECAR	  value,	   and	   lactate	   production	   rate	  was	   corrected	   to	   the	  milligram	  protein	   in	   each	  XF96-­‐plate	  well.	   	  Thus,	  oxygen	  consumption,	  ECAR,	  enzymatic	   lactate,	  and	  protein	  were	  all	  measured	  from	  the	  same	  well.	  	  To	   assess	   oxygen	   consumption	   in	   the	   M3II	   clone	   a	   Presens	   Sensor	   Dish	   Reader	  (SDR)	   in	   an	   airtight	  Coy	  Laboratory	  Chamber	  was	  utilized	   (termed	   the	   SDR	  plus).	  	  The	  percentage	  of	  gas	  in	  the	  chamber	  was	  set	  at	  20%	  oxygen,	  5%	  CO2,	  and	  75%	  N2.	  	  125,000	   cells/ml	  were	   seeded	   in	   a	   24-­‐well	   PreSens	  OxoDish®	  plates	   in	   500	  ul	   of	  DMEM	  high	  glucose	  plus	  10%	  FBS	  and	  allowed	  to	  settle	  for	  3	  hours	  before	  addition	  of	   new	   DMEM	   high	   glucose	   10%	   FBS	   at	   which	   t=0.	   Cell	   #	   was	   assessed	   with	   a	  Millipore	  Scepter.	  	  The	  cell	  number	  per	  well	  was	  the	  same	  for	  BV-­‐2,	  M3LM	  and	  M3	  at	  time	  of	  initial	  seeding.	  	  While	  the	  cells	  incubated	  the	  SDR	  Plus	  assessed	  %	  O2	  at	  the	  bottom	  of	  the	  dish	  every	  3	  minutes	  for	  48	  hours.	  	  Since	  there	  is	  20%	  O2	  in	  the	  SDR	  plus	  environment	  (translating	  to	  >	  20	  %	  in	  the	  media),	  the	  %	  O2	  recorded	  in	  wells	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with	  cells	  is	  subtracted	  from	  no	  cell	  containing	  wells	  to	  yield	  the	  %O2	  consumed	  at	  48	  hours.	  	  
Western	  Blot	  For	  western	  blot	   analysis,	  VM-­‐M3+	  and	  VM-­‐M3–	   cells	  were	   lysed	   in	   ice-­‐cold	  RIPA	  lysis	  buffer	  containing	  1x	  TBS,	  1%	  Nonidet	  P-­‐40,	  0.5%	  sodium	  deoxycholate,	  0.1%	  SDS,	   and	  0.004%	  sodium	  azide	   supplemented	  with	  PMSF,	  protease	   inhibitor	  cocktail,	  and	  sodium	  orthovandate	  (Santa	  Cruz	  Biotechnology,	   Inc.,	  Santa	  Cruz,	  CA,	  USA).	   Lysis	   was	   performed	   on	   ice	   for	   30	   minutes.	   Protein	   was	   then	   obtained	   by	  centrifugation	   at	   12,000	   x	   g	   for	   20	  minutes	   at	   4°C.	   The	   amount	   of	   protein	   in	   the	  sample	   was	   determined	   using	   the	   Pierce	   BCA	   Protein	   Assay	   (Thermo	   Scientific).	  Samples	  containing	  20	  µg	  of	  protein	  were	  boiled	  in	  NuPAGE	  LDS	  Sample	  Buffer	  and	  separated	   on	   NuPAGE	   4%–12%	   bis-­‐Tris	   gels	   (Invitrogen).	   The	   proteins	   were	  electrophoretically	  transferred	  to	  a	  Low-­‐Flourescence	  PVDF	  Transfer	  Membrane	  at	  20	  V	  overnight	  at	  4°C.	  The	  membrane	  was	  blocked	  in	  Odyssey	  Blocking	  Buffer	  for	  1	  hour	   and	   then	   probed	   with	   antibodies	   against	   Complex	   IV,	   subunit	   IV	   (1:2,000)	  (clone	  20E8;	  Molecular	  Probes,	  Eugene,	  Oregon,	  USA),	  LDHA	  (1:1,000)	  (#2012S;	  Cell	  Signaling	   Technology,	   Danvers,	   MA,	   USA),	   and	   β-­‐actin	   (1:7,500)	   (Clone	   AC-­‐74;	  Sigma-­‐Aldrich)	   overnight	   at	   4°C.	   The	   blots	   were	   then	   incubated	   with	   the	  corresponding	   Odyssey	   secondary	   antibodies	   Goat	   anti-­‐Rabbit	   IRDye	   800CW	  (1:20,000)	   (827-­‐08365)	   and	   Donkey	   anti-­‐Mouse	   IRDye	   800CW	   (1:20,000)	   (926-­‐32212)	   (LI-­‐COR	   Biosciences).	   The	   proteins	   were	   visualized	   using	   the	   Odyssey	  Classic	   imaging	   system	   (LI-­‐COR	   Biosciences).	   The	   intensity	   of	   each	   band	   was	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determined	   using	   Image	   Studio	   Lite	   software	   (LI-­‐COR	   Biosciences).	   Complex	   IV,	  subunit	   IV	   and	   LDHA	   expression	   were	   normalized	   to	   the	   intensity	   of	   the	   β-­‐actin	  band.	  Statistical	  analysis	  was	  performed	  using	  IBM	  SPSS	  Statistics	  software.	  A	  two-­‐tailed	   t-­‐test	   was	   performed	   and	   the	   significance	   values	   were	   determined	   for	   the	  ratios	  of	   both	  Complex	   IV,	   subunit	   IV	   and	  LDHA	   to	  β-­‐actin	   for	  both	  VM-­‐M3	  +	   and	  VM-­‐M3	  –	  cells.	  	  	  
Protein	  Quantification	  For	  protein	  determination	  of	  Seahorse	  XF96	  assay	  plates,	  40	  µl	  of	  RIPA	  lysis	  buffer	  (described	  above	  in	  detail	   for	  Western	  Blot)	  was	  added	  to	  each	  aspirated	  well	  and	  mixed	  by	  pipetting	  up	  and	  down	  25	   times.	   	  The	  plates	  were	   then	   incubated	  on	  an	  orbital	  shaker	  for	  15	  minutes	  at	  200	  rpms.	  	  The	  mixing	  step	  was	  repeated,	  the	  plate	  was	  incubated	  on	  ice,	  and	  the	  protein	  was	  subsequently	  quantified	  using	  25	  µl	  in	  the	  Pierce	   BCA	   Protein	   Assay	   (ThermoScientific)	   according	   to	   the	   manufacture’s	  protocol.	   	   Protein	   quantification	   for	   proliferation	   assays	   was	   done	   in	   the	   same	  manner.	  	  	  	  
Proliferation	  and	  Luminescence	  Output	  Assays	  ATP	  determination	  over	  2	  days	   in	  black	  walled	  96-­‐well	   cell	   culture	   treated	  plates	  was	  used	   to	  assess	   in-­‐vitro	  proliferation	  of	  M3+	  and	  M3—	  cells	   initially	   seeded	  at	  15,000	   cells/well.	   The	   cooled	   CCD	   camera	   on	   the	   Xenogen	   IVIS	   Lumina	   system	  (Xenogen,	   Hopkington,	   MA)	   was	   used	   to	   record	   the	   photons	   /	   second	   (over	   10	  seconds)	   emitting	   from	   a	   luminescence	   reaction	   after	   performing	   a	   CellTiter-­‐GLO	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Luminescent	   ATP	   assay	   (Promega,	   Madison,	   Wisconsin)	   according	   to	   the	  manufacture’s	  protocol.	   	   In	  addition,	   in-­‐vitro	  proliferation	  over	  5	  days	  of	  M3+	  and	  M3-­‐	  cells	  seeded	  at	  5,000	  cell/well	  in	  96-­‐well	  cell	  culture	  plates	  was	  assessed	  using	  a	  Pierce	  BCA	  protein	  assay.	  	  At	  1,	  3,	  and	  5	  days	  the	  protein	  was	  collected	  from	  each	  well	   as	   described	   in	   Protein	   Quantification	   section	   above.	   	   For	   the	   luminescent	  output	  assay	  the	  same	  procedure	  as	  the	  ATP	  proliferation	  assay	  was	  used,	  however	  with	   the	   following	   changes:	   rather	   than	   the	   CellTiter-­‐GLO	   assay,	   the	   M3	   cell	  endogenous	   firefly	   luciferase	  vector	  and	  added	  D-­‐luciferin	   (Promega)	  was	  used	   to	  initiate	  the	  bio-­‐luminescence	  reaction.	  	  Also,	  cells	  were	  not	  allowed	  to	  proliferate	  as	  the	   bio-­‐luminescence	  was	   gauged	   at	   4	   hours	   after	   seeding	  M3+	   or	  M3-­‐	   cells	   (M3	  cells	  attach	  to	  the	  bottom	  of	  the	  dish	  in	  ~	  2	  hours).	  	  During	  the	  luminescence	  output	  assay	  progressive	  microgram	  amounts	  of	  luciferin	  were	  added	  to	  a	  120ul	  of	  growth	  media	  with	  30,000	  cells	  /	  well	  in	  a	  black	  walled	  96-­‐well	  cell	  culture	  treated	  plate.	  	  	  	  
Mice	  Mice	  of	  the	  VM/Dk	  (VM)	  strain	  were	  obtained	  as	  gifts	  from	  G.	  Carlson	  (McLaughlin	  Research	   Institute,	   Great	   Falls,	   Montana)	   and	   from	   H.	   Fraser	   (University	   of	  Edinburgh,	  Scotland).	  All	  VM	  mice	  used	   in	  this	  study	  were	  housed	  and	  bred	   in	  the	  Boston	   College	   Animal	   Care	   Facility	   using	   husbandry	   conditions	   as	   described	  previously	  (57).	  	  All	  animal	  procedures	  were	  in	  strict	  accordance	  with	  the	  NIH	  Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  and	  were	  approved	  by	  the	  Institutional	  Animal	  Care	  Committee.	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Subcutaneous	  inoculation	  of	  M3+	  and	  M3-­‐	  cells	  The	  M3+	  and	  M3-­‐	  cell	  lines	  were	  grown	  to	  confluency	  in	  245	  mm	  cell	  culture	  dishes,	  scraped	  in	  PBS	  containing	  25	  mM	  glucose	  and	  4	  mM	  glutamine	  (PBS+),	  washed	  and	  then	   re-­‐suspended	   in	   PBS+.	   	   Subsequently,	   1.5	   million	   M3+	   or	   M3-­‐	   cells	   were	  subcutaneously	  injected	  in	  a	  0.5	  mL	  volume	  of	  PBS	  into	  the	  back	  or	  flank	  region	  of	  VM/Dk	  mice.	  	  
Assessment	  of	  tumor	  progression	  in	  VM	  mice	  
Morbidity	  of	  VM/Dk	  mice	  was	  used	  as	  an	  endpoint	  to	  in-­‐vivo	  experiments	  I,	  II,	  and	  the	  metastasis/survival	  study	  using	  M3II	  clones.	   	  However,	   in	  experiments	  I	  and	  II	  M3-­‐	   inoculated	   mice	   were	   not	   morbid	   but	   were	   sacrificed	   in	   order	   to	   compare	  tumor	   progression	   to	   M3+	   inoculated	   mice.	   For	   experiments	   I	   and	   II,	   primary	  tumors	  were	  excised,	   frozen,	  and	  weighed.	   	   In	   the	  metastasis/survival	  study	  using	  M3II	   clones,	   mice	   were	   imaged	   with	   the	   Xenogen	   IVIS	   Lumina	   system	   (Xenogen,	  Hopkington,	  MA)	  to	  record	  the	  bioluminescent	  photon	  signal	  from	  the	  VM-­‐M3/Fluc	  tumors.	   For	   in	   vivo	   whole	   body	   imaging	   in	   the	  metastasis	   /	   survival	   study,	   mice	  received	  an	  i.p.	  injection	  of	  D-­‐luciferin	  (50	  mg/kg,	  Xenogen)	  and	  Avertin	  (0.1	  ml/10	  g)	   and	   mice	   were	   imaged	   for	   1	   minute.	   	   For	   ex	   vivo	   imaging	   during	   in-­‐vivo	  experiment	  II,	  the	  brain	  was	  excised	  and	  placed	  in	  a	  Petri	  dish	  with	  300	  mg/ml	  D-­‐luciferin	  in	  PBS,	  and	  imaged	  for	  10	  seconds.	  	  
Extraction	   of	   Metabolites	   and	   Capillary	   Electrophoresis	   Time-­‐of-­‐Flight	   Mass	  
Spectrometry	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Results	  	  
Discovery	  and	  Eradication	  of	  Mycoplasma	  Infection	  in	  VM-­‐M3	  cells	  Mycoplasma	   infection	   in	   VM-­‐M3	   cells	   was	   first	   diagnosed	   enzymatically	   with	   a	  MycoAlert®	   Mycoplasma	   Detection	   Kit	   (data	   not	   shown).	   	   In	   light	   of	   a	   positive	  infection,	  the	  VM-­‐M3	  cells	  are	  referred	  to	  as	  VM-­‐M3+	  (abbreviated	  M3+).	  To	  verify	  the	   enzymatic	   detection	   of	   mycoplasma,	   PCR	   amplification	   of	   a	   260	   bp	   region	   of	  mycoplasmal	   16S	   rDNA	   gene	   was	   performed	   using	   primers	   able	   to	   identify	   182	  species	  of	  mycoplasma.	  	  Positive	  amplification	  indicative	  of	  a	  positive	  infection	  was	  seen	  by	   the	  presence	  of	   a	  260	  bp	  band	   in	   the	  +control	   and	  M3+	   lane	   (Figure	  1A).	  	  After	  eradication	  of	  mycoplasma	  infection	  with	  mycoplasma-­‐targeted	  antibiotics,	  no	  band	   at	   260	   bp	   could	   be	   detected	   indicating	   a	   successful	   eradication	   (M3-­‐	   lane).	  After	  eradication	  and	   in	   light	  of	  a	  negative	   infection,	   this	  cell	   line	  was	  named	  M3-­‐.	  	  Three	  weeks	  after	  eradication,	  the	  M3-­‐	  cells	  remained	  free	  of	  mycoplasma	  infection	  (Figure	  1B).	  	  
Mycoplasma	  arginini	  infection	  of	  VM-­‐M3	  cells	  The	  260	  bp	  region	  of	  amplified	  mycoplasmal	  16S	  rDNA	  gene	  from	  the	  infected	  M3+	  cells	  was	  excised	  from	  the	  gel,	  purified,	  and	  sequenced.	  	  BLAST	  was	  used	  to	  align	  the	  mycoplasmal	   16S	   rDNA	   (query)	   to	   subject	   sequences	   in	   GenBank.	   	   The	   top	   score	  identified	   the	   query	   sequence	   as	   derived	   from	  Mycoplasma	   arginini	   (Figure	   2A).	  	  The	   16S	   sequence	   belonging	   to	   Mycoplasma	   hominis,	   a	   phylogenetically	   close	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relative	   to	  M.	   arginini,	   (2)	   received	   a	   lower	   score	   in	   light	   of	   the	   mismatch/gap	  alterations	  (Figure	  2B).	  	  
Influence	  of	  M.	  arginini	  on	  respiration	  in	  VM-­‐M3	  cells	  According	   to	   bioenergetics	   principles	   mammalian	   cells	   are	   able	   to	   respire	   amino	  acids	  and	  fatty	  acids	  for	  energy	  (15)	  (Figure	  3).	  In	  order	  to	  compare	  the	  respiratory	  systems	  in	  M3+	  and	  M3-­‐	  cells,	  a	  Seahorse	  XF96	  analyzer	  was	  utilized	  (Figure	  4).	  	  In	  the	   presence	   of	   amino	   acids,	   fatty	   acids,	   and	   glucose	   (complete	   media)	   the	  eradicated	   M3-­‐	   cells	   show	   an	   elevated	   respiration	   rate	   compared	   to	   the	   infected	  M3+	  cells	  (Figure	  5A).	  Oxygen	  consumption	  rate	  dropped	  by	  84%	  and	  85%	  in	  M3+	  and	  M3-­‐	  cells,	  respectively,	  following	  addition	  of	  the	  respiratory	  inhibitor	  Antimycin	  A	   (AntA).	   	   Thus,	   approximately	   15%	   of	   oxygen	   consumption	   in	   both	   cell	   lines	   is	  unassociated	  with	  respiration	  in	  complete	  media.	  M.	  arginini	  eradication	  in	  M3-­‐	  cells	  elevated	   respiration	   by	   29%,	   after	   subtracting	   the	   AntA	   insensitive	   oxygen	  consumption.	  	  Extracellular	  acidification	  rate	  (ECAR)	  is	  often	  used	  to	  estimate	  lactate	  fermentation.	  	  However,	   ECAR	   is	   an	   indirect	   measure	   of	   lactate	   fermentation	   as	   the	   protons	  expelled	  with	   lactate	   are	  measured	   rather	   than	   lactate.	  ECAR	   is	  higher	   in	   the	  M3-­‐	  cells	   than	   in	   the	  M3+	  cells	   and	   fails	   to	   elevate	  under	  AntA	   treatment	   in	  M3+	  cells	  (Figure	   5B).	   Direct	   enzymatic	   measurement	   of	   L-­‐lactate	   is	   preferred	   as	   a	   more	  reliable	  measure	  of	  lactate	  fermentation	  rate	  as	  many	  factors	  can	  influence	  pH	  other	  than	  lactate	  efflux.	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  As	   an	   alternative	   to	   ECAR,	   an	   enzymatic	   assay	   was	   used	   to	   estimate	   lactate	  production	  (a	  measure	  of	  fermentation).	  Unlike	  the	  ECAR	  value,	  lactate	  production	  increased	   in	  M3+	  when	   respiration	  was	   inhibited	   by	   AntA,	   as	  would	   be	   expected	  (Figure	   5C).	   Lactate	   production	  was	   greater	   in	  M3-­‐	   cells	   than	   in	  M3+	   cells	   in	   the	  presence	  of	  AntA.	  	  No	  difference	  in	  lactate	  production	  was	  found	  between	  M3+	  and	  M3-­‐	  when	  lactate	  production	  was	  corrected	  to	  protein	  levels	  (Figure	  5C).	  	  However,	  when	   lactate	   production	   was	   corrected	   to	   ATP	   levels	   and	   cell	   number,	   M3-­‐	   cells	  made	   less	   lactate	   than	  M3+	  cells	   (Figure	  6).	  When	  compared	   to	   the	  M3+	  cells,	   the	  reduced	   lactate	   production	   by	   M3-­‐	   cells	   is	   in	   agreement	   with	   their	   higher	  respiration	   rate.	   	   The	   lower	   respiration	   and	   higher	   fermentation	   of	   M3-­‐	   cells	  compared	   to	  M3+	   cells	   is	   unable	   to	   be	   explained	   by	   differences	   in	   Cytochrome	   C	  Oxidase	  and	  LDHA	  protein	  levels	  (Figures	  7A-­‐&D)	  	  
Influence	  of	  M.	  arginini	  on	  the	  Crabtree	  effect	  in	  VM-­‐M3	  cells	  Cancer	  cells	  and	  other	  non-­‐tumorigenic	  highly	  glycolytic	  cells	  experience	  a	  Crabtree	  effect,	  i.e.	  glucose-­‐induced	  suppression	  of	  respiration	  (58)	  (59)	  (60).	  Suppression	  in	  respiration	   from	   a	   Crabtree	   effect	   can	   be	   measured	   by	   using	   media	   devoid	   of	  glucose,	  since	  respiration	  becomes	  un-­‐suppressed	  (61).	  Both	  the	  M3+	  and	  the	  M3-­‐	  cells	   demonstrated	   a	   Crabtree	   effect	   when	   10	   mM	   glucose	   (+glc)	   was	   added	   to	  glucose-­‐absent	  media	  (-­‐glc)	  that	  consisted	  an	  amino	  acid	  mix,	  2	  mM	  glutamine,	  and	  albumin	  conjugated	   fatty	  acids	  (Figure	  8A).	   	  The	  M3+	  and	  M3-­‐	  cells	  experienced	  a	  21%	  and	  30%	  Crabtree	  effect,	  respectively,	  when	  solving	  for	  the	  %	  Crabtree	  effect	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equation	   of	  Wenner	   (59)	   (Table	   1	  &	   Figure	   8B).	   In	   other	  words,	   glucose	   addition	  suppressed	  the	  respiration	  of	  M3+	  and	  M3-­‐	  cells	  by	  21%	  and	  30%,	  respectively.	  	  	  Respiration	  rate	  measured	  during	  the	  Crabtree	  is	  misleading	  because	  of	  variability	  in	   %	   Crabtree	   effect	   of	   difference	   cell	   lines.	   	   Unsuppressed-­‐respiration	   (during	  Crabtree	  effect-­‐circumvention)	  is	  a	  more	  accurate	  indication	  of	  a	  cell	  lines	  maximum	  respiratory	   rate.	   During	   the	   Crabtree	   effect	   the	  M3-­‐	   cells	   have	   a	   29%	   increase	   in	  respiration	   compared	   to	   M3+	   cells.	   However,	   when	   the	   Crabtree	   effect	   is	  circumvented	  by	  glucose	  removal	  the	  M3-­‐	  cells	  show	  a	  37%	  increase	  in	  respiration	  over	   that	   of	  M3+	   cells	   (Figure	   8A).	   	   Regardless	   of	   the	   presence	   or	   absence	   of	   the	  Crabtree	  effect,	  M.	  arginini	  eradication	  results	  in	  a	  significant	  increase	  in	  respiration	  rate	  in	  VM-­‐M3	  cells.	  	  
Influence	  of	  M.	  arginini	  on	  activation	  metabolites	  in	  VM-­‐M3	  cells	  Several	   activation-­‐specific	   metabolic	   markers	   for	   macrophages	   are	   characterized	  and	  validated.	  	  Itaconic	  acid	  is	  a	  bactericidal	  product	  of	  activated	  macrophages	  (62)	  (63)	   (64).	  The	  production	  of	   itaconic	  acid	  dropped	  more	   than	   two-­‐fold	   in	   the	  M3-­‐	  cells	  compared	  to	  the	  M3+	  cells	  (Figure	  9).	   	  Another	  key	  metabolite	  recently	  found	  to	  be	  produced	  by	  activated	  macrophages	  is	  succinate,	  which	  is	  metabolized	  partly	  from	  GABA	  (the	  GABA	  shunt)	  (65).	  GABA	  and	  succinate	  was	  significantly	  reduced	  in	  M3-­‐	   cells	   compared	   to	   M3+	   cells	   (Figure	   10).	   In	   addition	   to	   itaconic	   acid	   and	  succinate,	  another	  indicator	  of	  macrophage	  activation	  is	  Nitric	  Oxide	  (NO)	  made	  by	  Nitric	   Oxide	   Synthase	   (NOS)	   by	   metabolism	   of	   arginine	   to	   citrulline	   (66)(67).	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Therefore,	   arginine	   metabolism	   to	   citrulline	   indicates	   NO	   production.	   	   In	   the	  infected	   M3+	   cells	   arginine	   metabolism	   to	   citrulline	   was	   detected	   compared	   to	  barely	  detectible	  arginine	  to	  citrulline	  metabolism	  in	  the	  M3-­‐	  cells	  (Figure	  11).	  	  	  	  
Influence	  of	  M.	  arginini	  on	  the	  in	  vitro	  proliferation	  of	  VM-­‐M3	  cells	  Elevated	   intra-­‐cellular	   metabolites	   of	   the	   Pentose	   Phosphate	   Pathway	   (PPP)	  metabolites	   are	   indicative	   of	   enhanced	   cellular	   proliferation,	   as	   the	   PPP	   supplies	  metabolic	  precursors	  for	  DNA	  and	  RNA	  synthesis	  (68).	  	  Glucose	  is	  the	  precursor	  for	  the	   synthesis	   of	   Ribose-­‐5-­‐Phosphate	   (R5P),	   Ribulose-­‐5-­‐Phosphate	   (Ru5P),	   and	  Phosphoribosyl	   Pyrophosphate	   (PRPP).	   	   R5P,	   Ru5P,	   and	   PRPP	   provide	   the	  necessary	   ribose	   for	   de	   novo	   nucleic	   acid	   synthesis	   (69).	   The	   M3+	   cells	   showed	  elevated	  intra-­‐cellular	  levels	  of	  the	  PPP	  metabolites	  R5P,	  Ru5P,	  and	  PRPP	  compared	  to	   the	  M3-­‐	   cells	   (Figure	  12).	   	  Reduced	   intra-­‐cellular	  PPP	  metabolite	   concentration	  was	  concomitant	  with	  a	  reduced	  proliferation	  rate	  at	  higher	  cell	  densities	  in	  the	  M3-­‐	  cells	   compared	   to	   the	  M3+	   cells	   (Figure	   13).	   Therefore,	   eradication	   of	  M.	  arginini	  resulted	  in	  a	  lower	  in-­‐vitro	  proliferation	  rate	  in	  M3	  cells	  only	  at	  high	  cell	  densities.	  
	  
Influence	  of	  M.	  arginini	  on	  the	  in	  vivo	  tumor	  growth	  of	  VM-­‐M3	  cells	  The	  M3+	   cells	  metastasize	   systemically	   following	   subcutaneous	   inoculation	   in	   the	  syngeneic	   VM/Dk	  mouse	   host.	   	  Approximately	   1.5	  million	  M3+	   or	  M3-­‐	   cells	   were	  inoculated	  subcutaneously	  in	  the	  back	  (experiment	  1)	  or	  the	  flank	  (experiment	  2)	  of	  the	  VM/Dk	  mice.	  Experiment	  1	  was	  terminated	  after	  21	  days	  and	  experiment	  2	  was	  terminated	   after	   30	   days	   when	   the	   mice	   with	   the	   M3+	   cells	   became	   moribund	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(reduced	  ambulation	  due	  to	  tumor	  burden).	  	  	  None	  of	  the	  mice	  inoculated	  with	  M3-­‐	  cells	  became	  moribund.	  	  Wet	  weight	  was	  less	  for	  the	  tumors	  produced	  from	  the	  M3-­‐	  cells	  than	  for	  the	  M3+	  cells	  (Figure	  14A	  &	  14B).	  	  	  
Influence	  of	  M.	  arginini	  on	  the	  in	  vivo	  metastasis	  of	  VM-­‐M3	  cells	  The	   M3+	   cells	   are	   tranduced	   with	   a	   firefly	   luciferase	   lentivirus	   vector	   under	   the	  control	  of	   the	  constitutive	  CMV	  promoter.	   	  By	   injecting	   luciferin	   into	  VM	  mice	   it	   is	  possible	   to	   monitor	   growth	   and	   movement	   of	   M3	   cells	   in-­‐vivo	   by	   detecting	   the	  emitting	   photons	   (Figure	   15).	   Oxygen	   is	   a	   necessary	   substrate	   for	   the	   luciferase	  light-­‐emission	   reaction.	   	   The	  M3+	   cells	   consumed	   less	   oxygen	   than	   the	   M3-­‐	   cells	  (Figures	  5	  and	  8A).	  	  In	  addition,	  the	  M3+	  cells	  produce	  less	  light	  than	  M3-­‐	  cells	  from	  the	  luciferase	  reaction	  (Figure	  16).	  	  	  	  In	  experiment	  2,	  metastasis	  to	  liver	  and	  brain	  was	  assessed.	   	  Metastatic	  nodules	  to	  liver	   and	  metastatic	   brain	   luminescence	  were	   qualitatively	   less	   in	  M3-­‐	   inoculated	  mice	   compared	   to	   M3+	   mice	   (Figure	   17).	   	   Brain	   luminescence	   in	   M3-­‐	   mice	   was	  reduced	  by	   a	   factor	   of	   2.66	   to	   account	   for	   the	   greater	   luminescence	  output	   of	   the	  M3-­‐	  cells	  compared	  to	  the	  M3+	  cells.	  	  
Influence	   of	  M.	   arginini	  on	   oxygen	   consumption	   and	   tumor	   progression	  in	   a	  
VM-­‐M3	  tumor	  variant	  clone	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Discussion	  	  
M.	  arginini-­‐infected	  M3	  cells	  produce	  metabolites	  suggestive	  of	  activation.	  
M.	  arginini	  produces	  a	  low	  molecular	  weight	  protein	  termed	  Macrophage-­‐Triggering	  Factor	   (MTF)	   that	   activates	   macrophages	   (70).	   Once	   activated,	   macrophages	   and	  microglia	   exert	   cytotoxic	   effects	   by	   releasing	   inflammatory	   mediators,	   such	   as	  arachidonic	  acid	  metabolites,	  interleukin-­‐1	  (IL-­‐1),	  nitric	  oxide	  (NO),	  reactive	  oxygen	  species	   (ROS),	   and	   tumor	   necrosis	   factor-­‐alpha	   (TNF-­‐α)	   (71)	   (72).	   	   In	   fact,	  macrophages	   are	   potent	   secretory	   cells	   that	   release	   a	   plethora	   of	   mediators	   in	  response	  to	  activation	  (73).	  One	  of	  these	  activation	  markers	  was	  recently	  shown	  to	  be	   itaconic	   acid	   (62),	  which	  was	   corroborated	   in	   a	   subsequent	   independent	   study	  (63).	  	   Itaconic	   acid	   is	   a	   small	   metabolite	   that	   inhibits	   bacterial	   isocitrate	   lyase	   as	  well	   as	   glycolysis	   via	   the	   inhibition	   of	   phosphofructokinase	   (64)	   (74)	   (75).	  Therefore,	   itaconic	   acid	   could	   be	   both	   a	   bactericidal	   and	   an	   anti-­‐glycolytic	  metabolite.	  	  The	  M3+	  cells	  produce	  more	  than	  two-­‐fold	  the	  amount	  of	  itaconic	  acid	  than	   M3-­‐	   cells	   suggesting	   that	   M3+	   cells	   have	   an	   elevated	   levels	   of	   activation	  compared	  to	  the	  M3-­‐	  cells	  (Figure	  8).	  	  	  	  	  Another	   metabolite	   made	   by	   activated	   macrophage	   cells	   is	   succinate	   (65).	   	   In	  activated	  bone	  marrow	  derived	  macrophage	  cells	  (BMDM)	  succinate	  is	  made	  partly	  through	  the	  GABA	  shunt,	  which	  shunts	  GABA	  metabolized	  from	  glutamate	  towards	  succinate	   production.	   The	   LPS-­‐induced	   succinate	   production	   of	   BMDM	   results	   in	  HIF-­‐1α	   stabilization,	   elevated	   glycolysis,	   and	   subsequent	   IL-­‐1β	   production.	   	   In	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addition,	  BMDM	  activation	  results	  in	  a	  down-­‐regulation	  of	  mitochondrial	  genes	  and	  up-­‐regulation	  of	  glycolytic	  genes	  suggesting	  that	  activation	  of	  BMDM	  leads	  to	  lower	  respiration	  and	  a	  higher	  fermentation.	  	  In	  agreement,	  a	  separate	  study	  documented	  that	  LPS/IFN-­‐γ	   -­‐activated	  macrophages	  also	  experience	  a	   shift	   from	  respiration	   to	  fermentation,	   however	   succinate	   efflux	   was	   not	   measured	   (66).	   	   In	   the	   present	  study,	  M3+	  macrophage	  cells	  showed	  elevated	  succinate	  efflux	  (Figure	  9)	  in	  addition	  to	   the	   previously	   discussed	   diminishment	   in	   respiration	   (Figures	   5A	   and	   8A).	  	  Altogether,	  the	  present	  study	  and	  previous	  studies	  (65)	  (66)	  	  indicate	  that	  	  activated	  macrophage	   cells	   experience	   a	   diminished	   respiration	   as	   well	   as	   an	   elevated	  succinate	  efflux.	   	  Therefore,	  elevated	  succinate	  efflux	   is	  either	  a	  direct	  response	  to	  macrophage	  activation	  or	  a	  direct	  response	  to	  a	  diminished	  respiration.	  	  Tumor	  cells	  with	   a	   TCA	   cycle	   respiratory	   defects	   also	   elevate	   succinate	   efflux	   (76).	   	   Further,	  succinate	  levels	  elevate	  in	  oxygen	  deprived	  diving	  animals,	  oxygen-­‐deprived	  rabbit	  heart,	   and	   oxygen-­‐deprived	   tumor	   cells	   (77)	   (78)	   (79).	   Thus,	   elevated	   succinate	  seems	   to	  be	  more	  of	   a	   response	   to	   a	   diminished	   respiration	   than	   to	   the	   activated	  state	  of	  macrophages.	  	  A	  likely	  scenario	  is	  that	  macrophage	  activation	  in-­‐vitro	  leads	  to	  a	  diminished	  respiration	  and	  a	  diminished	  respiration	  leads	  to	  elevated	  succinate	  efflux.	   	   	  Therefore,	  succinic	  acid	  is	  emerging	  as	  a	  candidate	  metabolic	  marker	  for	  a	  diminished	   respiration	   and	   a	   diminished	   respiration	   seems	   to	   be	   a	   response	   of	  activated	  macrophages	  in-­‐vitro.	  	  Arginine	   is	   also	   an	   important	   metabolite	   in	   macrophage	   cells,	   M.	   arginini	  metabolism,	   and	   the	   cancerous	   state	   (19)	   (80)	   (81)	   (82).	   	   In	   the	   present	   study,	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metabolomic	  analysis	  showed	  an	  arginine	  to	  citrulline	  metabolism	  in	  the	  M3+	  cells.	  	  Arginine	  to	  citrulline	  metabolism	  indicates	  the	  production	  of	  Nitric	  Oxide	  (NO).	  	  NO	  is	  a	  sign	  of	  macrophage	  activation	  and	   is	  made	  by	   inducible	  Nitric	  Oxide	  Synthase	  (iNOS),	  an	  enzyme	  that	  metabolizes	  O2,	  NADPH	  and	  arginine	  to	  water,	  citrulline	  and	  NO.	   	   Since	   NO	   is	   difficult	   to	   measure	   and	   because	   no	   other	   enzyme	   is	   known	   to	  metabolize	   arginine	   to	   citrulline	   in	  mammalian	   cells,	   NOS	   activity	   and	  NO	   can	   be	  conveniently	   assessed	   by	   measuring	   conversion	   of	   radio-­‐labeled	   arginine	   to	  citrulline	   (67).	   	   I	   speculate	   that	   the	  M3+	   cells	   are	   producing	  NO	  on	   the	   basis	   of	   a	  drop	  in	  arginine	  levels	  compared	  to	  the	  M3-­‐	  cells	  coupled	  with	  citrulline	  production,	  which	   is	   absent	   in	   the	   M3-­‐	   cells	   (Figure	   10).	   	   On	   the	   other	   hand	   the	   arginine	   to	  citrulline	  metabolism	  in	  the	  M3+	  cells	  may	  stem	  from	  the	  metabolism	  of	  M.	  arginini	  itself.	   	  Arginine	  deiminase	   from	  arginine-­‐utilizing	  mycoplasma	  like	  M.	  arginini	  also	  metabolizes	  arginine	  to	  citrulline.	  	  As	  a	  result	  arginine	  deiminase	  has	  been	  found	  to	  be	  masquerading	  as	  nitric	  oxide	  synthase	  in	  mycoplasma	  infected	  cultures	  (8).	  	  Thus	  it	   is	   unclear	  whether	   the	   arginine	   to	   citrulline	  metabolism	  measured	   in	  M3+	   cells	  indicates	   activation-­‐induced	   NO	   production	   or	   whether	   it	   is	   simply	   a	   product	  M.	  
arginini	  arginine	   deiminase	  metabolism.	   	   Activation-­‐induced	  NO	  production	   is	   the	  more	   likely	   scenario	   explaining	   arginine	   to	   citrulline	  metabolism	   since	   M3+	   cells	  also	   showed	   elevation	   of	   activation-­‐associated	   itaconic	   acid	   and	   succinate	  production.	   	   In	   agreement	  with	   the	   concept	   that	   arginine	   to	   citrulline	  metabolism	  results	   in	   NO	   production	   in	  M3+	   cells,	   the	   presence	   of	  M.	  arginini	   is	   sufficient	   to	  cause	  NO	  and	  TNF-­‐α	  production	  in	  macrophage	  cells	  (70)	  (83).	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Elevated	   proliferation	   associated	  with	  M.	  arginini	   infection	   is	   dependent	   on	  
high	  cellular	  density	  The	   enhanced	   proliferation	   in	   M3+	   cells	   is	   concomitant	   with	   an	   increase	   in	   the	  macrophage	   activation-­‐metabolites	   itaconic	   acid,	   succinate	   acid,	   and	   citrulline.	  	  	  However,	   M3+	   cells	   show	   no	   increase	   in	   proliferation	   in	   low-­‐density	   culture	  suggesting	  that	  M3+	  cells	  may	  not	  be	  activated	  at	  low	  cellular	  density.	  	  Therefore,	  M.	  
arginini	   only	   exerted	   its	  mitogenic	   effects	   at	   high	   cellular	   density.	   	   The	   increased	  proliferation	  of	  M3+	  cells	  over	  M3-­‐	  cells	  at	  high	  cell	  density	  could	  be	  a	  result	  of	  an	  activation	   product	   that	   concentrates	   in	   the	   culture	   media.	   	   For	   example,	  mycoplasmas	   have	   been	   shown	   to	   induce	   macrophages	   to	   secrete	   granulocyte-­‐	  monocyte	   colony	   stimulating	   factors	   (GM-­‐CSFs)	   (5),	   which	  may	   accrue	   in	   the	   cell	  culture	  media	  to	  cause	  proliferation	  during	  high-­‐density	  M3+	  cell	  culture.	   	  Further	  studies	  with	   the	  M3+	   cells	   in	   low	  and	  high	  density	  will	   be	  needed	   to	  uncover	   the	  mechanism	  behind	  the	   increase	  of	  high-­‐density	  proliferation	  of	   the	  M3+	  cells	  over	  that	  of	  the	  M3-­‐	  cells.	  	  
Crabtree	  effect-­‐induced	   suppressed	   respiration	   is	   separate	   from	  M.	  arginini-­‐
induced	  diminished	  respiration	  All	  cancer	  cells	  are	  known	  to	  experience	  a	  Crabtree	  effect	  and	  there	  is	  no	  mention	  in	  the	   literature	   of	   cancer	   cells	   that	   fail	   to	   do	   so	   (84)	   (85)	   (86).	   Normal	   non-­‐transformed,	   non-­‐tumorigenic	   cells	   do	   not	   experience	   a	   Crabtree	   effect	   (58)	   (59).	  	  Some	   activated	   immune	   cells	   experience	   a	   Crabtree	   effect	   (60),	   but	   it	   is	   unclear	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whether	   these	   Crabtree	   positive	   immune	   cells	   would	   persist	   to	   experience	   a	  Crabtree	  effect	  in	  the	  non-­‐activated	  state.	   	  The	  Crabtree	  effect	  seems	  to	  be	  derived	  from	  a	  over-­‐sensitive	  hyperactive	  glycolytic	  system	  that	  siphons	  the	  ADP	  pool	  away	  from	  respiration	  and	  thus	  suppresses	  respiration	  (59)	  (87),	  however	  it	  is	  unknown	  	  how	   this	   deregulation	   of	   glycolysis	   is	   initiated.	   	   Therefore	   the	   lactate	   produced	  during	  the	  Crabtree	  effect	  is	  not	  due	  to	  an	  increased	  glycolysis	  but	  rather	  from	  the	  suppressed	  respiration	  system.	  	  Since	  glucose	  is	  always	  present	  in-­‐vivo	  and	  in-­‐vitro,	  cancer	   cells	   experience	   a	   constant	   diminished	   respiration	   due	   to	   the	   suppressive	  effects	  of	  the	  Crabtree	  effect.	  In	  agreement,	  our	  study	  shows	  that	  both	  tumorigenic	  M3+	  cells	  and	  M3-­‐	  cells	  experience	  a	  Crabtree	  effect	  (Figure	  8A).	  	  It	  is	  unclear	  why	  M3+	  cells	  have	  a	  smaller	  %	  Crabtree	  effect	  than	  the	  M3-­‐	  cells	  (Table	  1),	  however	  a	  reduced	   Crabtree	   effect	   like	   seen	   in	   the	   M3+	   cells	   has	   been	   associated	   with	  uncoupling	  of	  respiration	  with	  phosphorylation	  of	  ADP	  (59).	   	  Thus	   in	  concordance	  with	  their	  tumorigenicity	  and	  as	  a	  result	  of	  the	  ubiquitous	  nature	  of	  glucose,	  both	  M.	  
arginini-­‐infected	  M3+	   cells	   and	   eradicated	  M3-­‐	   cells	   experience	   a	   glucose-­‐induced	  constitutive	  diminished	  respiration	  due	  to	  the	  Crabtree	  effect.	  	  In	  addition	  to	  the	  diminished	  respiration	  caused	  by	  the	  Crabtree	  effect,	  the	  infected	  M3+	   cells	   experience	   another	   separate	   reduction	   in	   respiration	   compared	   to	   the	  M3-­‐	  cells	  (Figure	  5A	  &	  7).	  Presumably	  the	  separate	  reduction	  in	  respiration	  is	  due	  to	  the	  presence	  of	  M.	  arginini.	   	   The	  M.	  arginini-­‐associated	   reduction	   in	   respiration	  of	  the	  M3+	   cells	   is	   separate	   from	   the	   reduction	   caused	   by	   the	   Crabtree	   effect.	   	   As	   a	  result	   the	  M.	   arginini-­‐associated	   reduction	   in	   respiration	   is	   seen	   in	   the	   Crabtree	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positive	  condition	  (+glucose)	  and	  also	  when	  the	  Crabtree	  effect	   is	  circumvented	  (-­‐glucose).	  	  When	  the	  Crabtree	  effect	  is	  circumvented	  in	  both	  M3+	  and	  M3-­‐	  cells,	  the	  
M.	  arginini-­‐associated	   reduction	   in	   respiration	   is	   exacerbated	   (Figure	   7:	   Compare	  M3+	  and	  M3-­‐	  minus	  glucose	  condition).	  	   	  Thus,	  the	  M3+	  cells	  exhibit	  two	  insults	  to	  respiration,	  one	  being	  the	  Crabtree	  effect	  and	  the	  other	  being	  the	  “M.	  arginini	  effect”	  per	  se.	  	  	  
Diminished	  respiration	  is	  concomitant	  with	  enhanced	  fermentation	  in	  VM-­‐M3	  
cells	  infected	  with	  M.	  arginini	  	  Respiration	   and	   fermentation	   negatively	   regulate	   each	   other	   and	   therefore	   are	  intrinsically	   linked.	   	   For	   example,	   during	   the	   Crabtree	   effect	   glucose	   induces	   an	  over-­‐active	  fermentation	  and	  as	  a	  result	  the	  respiration	  system	  is	  suppressed	  (59).	  	  In	  agreement,	  hypoxia	  and	  respiratory	  inhibitors	  halt	  respiration	  and	  fermentation	  is	   up-­‐regulated	   to	   energetically	   compensate	   for	   lost	   respiration.	   	   However,	   the	  reduced	   respiration	  of	  M3+	  cells	   compared	   to	  M3-­‐	   cells	   is	  not	  accompanied	  by	  an	  increase	   in	   fermentation	   after	   correction	   of	   the	   fermentation	   rate	   (lactate	  production)	  to	  the	  milligrams	  of	  protein	  (Figure	  5C).	  	  Similarly,	  the	  M3+	  cells	  would	  be	  expected	  to	  increase	  lactate	  fermentation	  rate	  to	  the	  same	  extent	  as	  the	  M3-­‐	  cells	  when	  challenged	  with	  the	  respiratory	  inhibitor	  Antimycin	  A,	  but	  M3+	  cells	  produce	  significantly	   less	   lactate	   than	   the	   M3-­‐	   cells	   (Figure	   5C	   +	   Ant	   A	   condition).	   The	  possibility	  exists	  that	  M.arginini	   is	  respiring	  the	  lactate	  produced	  by	  M3+	  cells	  and	  thus	  an	  increase	  in	  fermentation	  rate	  would	  be	  masked.	  	  Respirometry	  studies	  have	  shown	   that	   both	   fermentative	   and	   non-­‐fermentative	   mycoplasmas	   can	   respire	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lactate	  and	  various	  other	  metabolic	  fuels	  for	  energy.	  	  M.	  hominis,	  a	  non-­‐fermentative	  mycoplasma	  similar	  to	  M.	  arginini	  ,	  is	  able	  to	  respire	  butyryl-­‐CoA,	  succinate,	  NADH,	  NADPH	   and	   lactate	   (88)	   (89).	   The	   fermentative	  M.	   gallisepticum	   can	   also	   respire	  lactate	  and	  various	  other	  mycoplasma	  species	  have	  been	  shown	  to	  respire	  ethanol,	  glucose,	   acetate,	   and	   short	   chain	   fatty	   acids	   (90).	   	   Therefore,	   M.	   arginini	   could	  possibly	  be	  respiring	  the	  lactate	  produced	  by	  M3+	  giving	  the	  false	   impression	  that	  fermentation	   rate	   is	   not	   increasing.	   	   The	   possibility	   that	  M.	  arginini	   is	   interfering	  with	  lactate	  measurements	  in	  the	  this	  study	  is	   in	  agreement	  with	  previous	  reports	  on	  mycoplasma	  falsifying	  many	  metabolic	  and	  non-­‐metabolic	  cellular	  assays	  (8)	  (9)	  (10).	  	  	  Another	  more	  substantiated	  reason	  that	  M.	  arginini	  could	  be	  interfering	  with	  lactate	  measurements	   is	   the	   fact	   that	   lactate	   production	   was	   corrected	   to	   the	   milligram	  protein	  and	  that	  the	  protein	  content	  of	  M3+	  cells	  could	  be	  overestimated	  due	  to	  the	  addition	   of	   M.	   arginine-­‐derived	   protein.	   	   For	   example,	   if	   M.	   arginini	   protein	  amounted	   to	  10%	  of	   the	   total	  M3+	  protein	  quantified	   then	   the	  actual	  M3+	  protein	  would	  be	  incorrectly	  overestimated.	  	  An	  overestimation	  of	  M3+	  protein	  results	  in	  an	  underestimation	  of	   the	   fermentation	   rate	   (nmoles	   lactate	   /	   hr	   /	  mg	  protein	   value	  used	  in	  Figure	  5C).	  	  In	  support	  of	  this	  notion,	  the	  extracellular	  lactate	  concentration	  measured	  by	  mass	   spectrometry	  was	  greater	   for	  M3+	  cells	   compared	   to	  M3-­‐	   cells	  since	   the	   mass	   spectrometry	   data	   was	   corrected	   to	   cell	   number	   rather	   than	   to	  milligram	   protein	   (Figure	   18A).	   	   Additional	   evidence	   that	   M3+	   cells	   increase	  fermentation	   in	   response	   to	   diminished	   respiration	   is	   derived	   from	   studies	   done	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with	  M3II	  cells,	  a	  different	  clone	  than	  M3	  but	  derived	  from	  the	  same	  initial	  VM-­‐M3	  tumor.	  	  Enzymatic	  lactate	  measurements	  were	  greater	  in	  M3II+	  cells	  than	  M3II-­‐	  cells	  when	  corrected	  to	  ATP	  levels	  (Figure	  18B),	  suggesting	  that	  a	  decrease	  in	  respiration	  occurred	  in	  conjunction	  with	  an	  increase	  in	  fermentation.	  Ultimately,	  cellular	  assays	  done	   with	   mycoplasma-­‐infected	   cell	   cultures	   need	   to	   be	   corrected	   by	   multiple	  parameters	   unless	  mycoplasma	  protein	   amount	   can	   be	   accurately	   separated	   from	  cellular	  protein	  amount	  in	  the	  assay	  being	  performed.	   	  Nonetheless,	  the	  possibility	  exists	   that	   in	   the	   present	   study	  M.	   arginini	   is	   interfering	   with	   lactate	   production	  when	  corrected	  to	  the	  milligram	  of	  cellular	  protein.	  	  
Possible	  mechanism	  of	  M.	  Arginini-­‐induced	  diminished	  respiration.	  The	  mechanism	  behind	   the	  decline	   in	   respiration	  by	   the	  M.	  arginini	   effect	  on	  M3+	  cells	   is	  unknown.	   	  It	  seems	  clear	  that	  the	  diminished	  respiration	  by	  the	  M.	  arginini	  effect	   involves	   activation	   of	   M3	   macrophage	   cells	   since	  M.	   arginini	   is	   capable	   of	  activating	   macrophages	   (70).	   Both	   M.	   arginini-­‐activated	   and	   LPS-­‐activated	  macrophages	   have	   been	   shown	   to	   release	   NO	   (70)	   (71)	   and	   other	   mycoplasma	  species	   can	   also	   induce	   NO	   release	   in	   macrophage	   cells	   (91).	   	   NO	   is	   a	   powerful	  respiratory	   inhibitor	   (92).	   Activated	   macrophages	   have	   been	   shown	   to	   severely	  diminish	  the	  respiration	  of	  six	  different	  cancer	  cell	  lines	  during	  co-­‐culture,	  however	  the	  implications	  of	  NO	  were	  not	  discussed	  (93).	  In	  addition,	  activated	  macrophages	  are	  capable	  of	  injuring	  neurons	  partly	  through	  NO	  production,	  possibly	  diminishing	  neuronal	  respiration	  (71).	   	  Therefore	  activated	  macrophage	  metabolism	  in-­‐vitro	   is	  sufficient	   to	   diminish	   the	   respiration	   system	   of	   co-­‐cultured	   cells,	   partly	   do	   to	   NO	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production.	   	   If	   activated	  macrophages	   can	   diminish	   the	   respiration	   of	   co-­‐cultured	  cells	  then	  it	  should	  be	  possible	  that	  they	  are	  at	  the	  same	  time	  diminishing	  their	  own	  respiration	  in-­‐vitro.	  Thus,	  perhaps	  the	  diminished	  respiration	  in	  M3+	  cells	  is	  in	  part	  self-­‐promoted	   by	   activation-­‐induced	   NO	   production.	   If	   this	   scenario	   were	   true,	   it	  would	  mean	  that	  M.	  arginini	  activates	  M3+	  cells	  and	  as	  a	  result	  M3+	  cells	  produce	  NO	  that	  diminishes	  their	  own	  respiration	  as	  well	  as	  the	  respiration	  of	  neighboring	  M3+	   cells.	   	   It	   has	   indeed	   been	   shown	   that	   activated	   macrophages	   experience	   a	  diminished	  respiration	   in-­‐vitro	  (65)	   (66),	  but	   it	   is	  unclear	  whether	   the	  diminished	  respiration	   is	   a	   natural	   part	   of	   macrophage	   activation-­‐induced	   catabolism	   or	   is	  rather	   an	   effect	   from	   an	   inflammatory	   secreted	   molecules	   such	   as	   NO	   or	   TNF-­‐α	  (TNF-­‐α	  also	  disrupts	  respiratory	  energy	  production	  (94)).	  	  	  
Potential	  mechanism	  of	  M.	  arginini-­‐induced	  tumor	  progression	  As	  mentioned	   above,	   the	   present	   study	   suggests	   that	   the	   presence	   of	  M.	   arginini	  leads	   to	   activation	   of	   M3	   cells,	   a	   concomitant	   inflammatory	   response,	   and	   a	  diminished	   respiration.	   	   As	   tumor-­‐promoting	   inflammation	   is	   an	   enabling	  characteristic	  of	  the	  hallmarks	  of	  cancer	  and	  deregulation	  of	  cellular	  energetics	  is	  an	  emerging	   hallmark	   of	   cancer,	   NO	   and	   TNF-­‐α	   production	   by	  M3+	   cells	   is	   perhaps	  leading	  to	  their	  diminished	  respiration.	  	  M.	  arginini	  induced	  inflammation	  in	  vivo	  is	  partly	   a	   probable	   cause	   of	   the	   tumor	   progression	   increase	   seen	  when	   inoculating	  M3+	  cells	  in-­‐vivo	  compared	  to	  M3-­‐	  cells.	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Therapeutic	  Implications	  Mycoplasmas	   can	   be	   detected	   in	   a	   high	   percentage	   of	   a	   wide	   variety	   of	   primary	  human	   cancers	   (42)	   (43)	   (44)	   (45).	   	   Some	  mycoplasma	   species	   can	   cause	   cells	   in	  culture	   to	   be	   tumorigenic	   but	   studies	   injecting	   these	   species	   into	   animals	   and	  assessing	   any	   cancer	   causing	   potential	   or	   cancer	   promoting	   potential	   are	   lacking.	  	  	  However,	  mycoplasmas	  enable	  many	  of	   the	  hallmarks	  of	   cancer	   (5)	   (31)	   (32)	   (24)	  (33)	   (34)	   (35)	   (37)	   (38)	   (39)	   (40),	   	  and	  thus	  mycoplasma-­‐targeted	  therapies	  could	  offer	   relief	   from	   progression	   and	   thus	   more	   time	   to	   patients	   with	   mycoplasma-­‐infected	   cancers.	   For	   example,	   55%	   of	   glioblastoma	   specimens	   (out	   of	   35)	   tested	  positive	  for	  cytomegalovirus	  (95)	  and	  when	  antivirals	  against	  cytomegalovirus	  were	  given	   to	   glioblastoma	  patients,	   survival	   significantly	   improved	   (96).	   	   Interestingly,	  cytomegalovirus	  induces	  bio-­‐energetic	  changes	  reminiscent	  of	  M.	  arginini	   infection	  in	  M3	  cells	  (97)	  (98)	  (99).	  	  The	  present	  study	  warrants	  further	  investigation	  into	  the	  role	  mycoplasmas	   play	   in	   human	   cancer	   and	   to	   the	   extent	   in	   which	  mycoplasma	  infections	   present	   in	   human	   cancer.	   	   If	   mycoplasmas	   are	   found	   to	   play	   a	   major	  causative	  or	  provocative	  role	  in	  human	  cancer	  in	  a	  variety	  of	  cancers,	  mycoplasma-­‐targeted	   therapies	   could	  prove	   efficacious	   in	  prevention	  of	   cancer	   and	  prolonging	  mycoplasma-­‐infected	  patient	  survival.	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Figure	  1.	  Eradication	  of	  Mycoplasma	  Infection	  in	  VM-­‐M3	  cells.	  (A)	  A	  1.5%	  agarose	  gel	  with	  amplified	  DNA	  products	  which	  include	  a	  positive	  control	  (+cont),	  the	  infected	  M3	  cells	  (M3+),	  the	  eradicated	  M3	  cells	  (M3—)	  and	  the	  negative	  control	  (cell	  growth	  media).	  The	  top	  band	  at	  570	  bp	  is	  an	  amplified	  Human	  /	  Mammalian-­‐specific	  DNA	  sequence	  controlling	  for	  the	  presence	  of	  human	  or	  mammalian	  cells.	  	  The	  260	  bp	  band	  is	  the	  amplified	  extracted	  16S	  rDNA	  gene	  capable	  of	  identifying	  182	  Mycoplasma	  species.	  	  The	  lower	  faint	  band	  is	  an	  amplified	  internal	  control	  band	  of	  an	  artificial	  gene	  derived	  from	  the	  human	  TNFα	  gene.	  	  MycoZap	  (Lonza)	  and	  a	  subsequent	  treatment	  with	  ciprofloxacin	  were	  used	  to	  eradicate	  the	  infection	  (M3—).	  The	  positive	  control	  is	  amplified	  extracted	  DNA	  from	  Mycoplasma	  fermentans	  infected	  K562	  cells.	  The	  negative	  control	  is	  fresh	  DMEM	  high	  glucose	  plus	  10%FBS.	  (B)	  The	  eradication	  was	  stable	  for	  up	  to	  three	  weeks	  in	  culture	  without	  the	  use	  of	  prophylactic	  methods.	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Figure	  1	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Figure	  2.	  Infection	  of	  VM-­‐M3	  cells	  by	  Mycoplasma	  arginini.	  (A)	  The	  sequenced	  DNA	  code	  of	  the	  excised	  260	  bp	  amplified	  band	  of	  mycoplasmal	  16S	  rDNA	  of	  the	  M3+	  cells.	  	  The	  mycoplasmal	  16S	  rDNA	  sequence	  (query)	  was	  blasted	  and	  the	  best	  match	  (subject)	  was	  Mycoplasma	  arginini.	  	  Red	  stars	  indicate	  a	  mismatch	  or	  gap	  in	  the	  query	  compared	  to	  that	  of	  the	  subject.	  (B)	  The	  query	  rDNA	  sequence	  was	  aligned	  with	  a	  closely	  phylogenetic	  related	  species,	  i.e.	  Mycoplasma	  hominis,	  verifying	  the	  query	  rDNA	  sequence	  does	  not	  closely	  match	  other	  related	  mycoplasma	  species	  (6	  red	  stars	  for	  M.	  hominis	  and	  1	  for	  M.arginini).	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Figure	  2	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Figure	  4.	  Measurement	  of	  energy	  catabolism	  with	  a	  Seahorse	  XF-­‐96	  Flux	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Figure	  4	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Figure	  5.	  Comparison	  of	  oxygen	  consumption,	  ECAR,	  and	  lactate	  production	  of	  
M3+	  and	  M3—	  cells	  in	  the	  presence	  and	  absence	  of	  Antimycin	  A.	  	  Oxygen	  consumption	  rate	  (A)	  Extracellular	  acidification	  rate	  (ECAR)	  (B),	  and	  Lactate	  production	  rate	  (C)	  in	  M3+	  and	  M3—	  cells.	  	  Complete	  media	  is	  DMEM	  with	  2	  mM	  glutamine,	  10	  mM	  glucose,	  and	  0.5	  mg/mL	  Albumax	  I.	  	  No	  FBS	  and	  no	  bicarbonate	  was	  included	  as	  recommended	  by	  Seahorse	  for	  ECAR	  measurements.	  	  Phenol	  red	  was	  not	  included	  since	  visual	  pH	  monitoring	  was	  unnecessary.	  	  The	  concentration	  of	  Antimycin	  A	  was	  100	  nM.	  	  Oxygen	  consumption,	  ECAR,	  enzymatic	  lactate,	  and	  protein	  were	  all	  measured	  from	  the	  same	  well	  using	  a	  Seahorse	  XF96	  Analyzer.	  In	  the	  —Antymycin	  A	  condition	  n=8	  and	  in	  the	  +	  Antymycin	  A	  condition	  n=4.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01	  (determined	  by	  the	  two	  tailed	  student	  t-­‐test).	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Figure	  6.	  Lactate	  production	  of	  infected	  and	  eradicated	  M3	  and	  M3II	  cells	  	  (A)	  Relative	  area	  of	  extracellular	  lactate	  in	  the	  media	  after	  6	  hours	  of	  incubation	  with	  M3+	  or	  M3—	  cells	  in	  normal	  air.	  	  Metabolomic	  analysis	  was	  performed	  by	  Human	  Metabolome	  Technologies	  (HMT)	  using	  Capillary	  Electrophoresis	  Time-­‐of-­‐Flight	  Mass	  Spectrometry.	  	  All	  metabolomic	  analysis	  was	  done	  with	  an	  n=4.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  (B)	  Millimoles	  of	  lactate	  in	  media	  measured	  enzymatically	  after	  48	  hours	  of	  incubation	  in	  an	  airtight	  Coy	  Laboratory	  Chamber.	  	  The	  percentage	  of	  gas	  was	  set	  at	  20%	  oxygen,	  5%	  CO2,	  and	  75%	  N2.	  	  The	  graph	  represents	  the	  lactate	  production	  after	  48	  hours	  incubation	  corrected	  to	  ATP	  levels	  also	  taken	  at	  48hrs	  (n=5).	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01	  	  	  	  	  ***	  =	  p	  <	  0.001	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Figure	  7.	  LDHA	  and	  Cytochrome	  c	  Oxidase	  protein	  expression	  of	  M3+	  and	  
M3—	  cells.	  	  (A)	  Western	  blot	  (fluorescent	  secondary)	  of	  the	  M	  subunit	  of	  the	  Lactate	  Dehydrogenase	  enzyme	  encoded	  by	  the	  LDHA	  gene.	  	  (B)	  Western	  Blot	  (fluorescent	  secondary)	  of	  	  protein	  subunit	  IV	  of	  the	  Cytochrome	  c	  Oxidase	  protein.	  	  (C)	  Quantification	  of	  LDHA	  to	  B-­‐Actin	  levels	  in	  M3+	  versus	  M3—	  cells.	  (D)	  Quantification	  of	  Cytochrom	  C	  Oxidase	  to	  B-­‐Actin	  levels	  in	  M3+	  versus	  M3—	  cells.	  	  n=3	  for	  A-­‐D.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	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Figure	  8.	  The	  influence	  of	  glucose	  on	  the	  oxygen	  consumption	  of	  M3+	  and	  M3	  
—	  cells.	  	  (A)	  Oxygen	  consumption	  rate	  of	  M3+	  and	  M3—	  cells	  grown	  in	  the	  absence	  or	  presence	  of	  glucose	  (10mM)	  in	  media	  containing	  amino	  acids	  and	  fatty	  acids.(B)	  In	  order	  to	  quantify	  the	  Crabtree	  effect	  the	  %	  Crabtree	  effect	  equation	  was	  utilized	  from	  “Pasteur	  and	  Crabtree	  effects	  -­‐	  Assays	  in	  cells,	  Wenner	  1979”.	  QO2	  =	  the	  nmoles	  of	  O2	  consumed	  /	  hr	  /	  mg	  protein.	  Quantification	  of	  the	  %	  Crabtree	  effect	  is	  shown	  in	  table	  1.	  	  n=8	  for	  both	  —glc	  and	  +glc	  conditions	  for	  M3+	  and	  M3—	  cells.	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01	  	  (determined	  by	  the	  two	  tailed	  student-­‐test).	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Figure	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Figure	  9.	  	  Production	  of	  Itaconic	  acid	  by	  M3+	  and	  M3-­‐	  cells.	  	  Relative	  area	  of	  intracellular	  isocitrate,	  intracellular	  itaconic	  acid,	  and	  extracellular	  itaconic	  acid	  in	  the	  media	  after	  6	  hours	  of	  incubation	  with	  M3+	  or	  M3—	  cells.	  Control	  media	  had	  no	  cells	  but	  was	  incubated	  for	  the	  6	  hour	  period.	  	  Itaconic	  acid	  is	  a	  bactericidal	  metabolite	  produced	  by	  activated	  macrophages.	  	  Rather	  than	  cis-­‐aconitate	  producing	  isocitrate,	  activated	  macrophages	  seem	  to	  use	  cis-­‐aconitate	  to	  produce	  itaconic	  acid.	  Metabolomic	  analysis	  was	  performed	  by	  Human	  Metabolome	  Technologies	  (HMT)	  using	  Capillary	  Electrophoresis	  Time-­‐of-­‐Flight	  Mass	  Spectrometry.	  	  All	  metabolomic	  analysis	  was	  done	  with	  an	  n	  =	  4.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01.	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Figure	  9	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Figure	  10.	  	  Production	  of	  succinate	  via	  the	  GABA	  shunt	  by	  M3+	  and	  M3-­‐	  cells.  Relative	   area	   of	   intracellular	   GABA,	   intracellular	   succinate,	   and	   extracellular	  succinate	  in	  cell	  extractions	  or	  in	  the	  media	  after	  6	  hours	  of	  incubation	  with	  M3+	  or	  M3—	   cells.	   Control	   media	   had	   no	   cells	   but	   was	   incubated	   for	   the	   6	   hour	   period.	  	  Itaconic	   acid	   is	   a	   bactericidal	   metabolite	   produced	   by	   activated	   macrophages.	  	  Metabolomic	  analysis	  was	  performed	  by	  Human	  Metabolome	  Technologies	   (HMT)	  using	  Capillary	  Electrophoresis	  Time-­‐of-­‐Flight	  Mass	  Spectrometry.	  	  All	  metabolomic	  analysis	  was	   done	  with	   an	   n	   =	   4.	   	   Error	   bars	   represent	   95%	   confidence	   intervals	  calculated	  using	  Excel.	  	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01	  	  	  	  	  ***	  =	  p	  <	  0.001 	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Figure	  11.	  Production	  of	  Citrulline	  from	  Arginine	  in	  M3+	  and	  M3-­‐	  cells.	  Relative	  area	  of	  L-­‐arginine	  and	  citrulline	  in	  extracted	  intra-­‐cellular	  metabolites	  of	  M3+	  and	  M3—	  cells	  incubated	  in	  complete	  media	  for	  6	  hours.	  The	  relative	  area	  of	  citrulline	  in	  the	  M3—	  condition	  is	  at	  0.004,	  however	  the	  bar	  is	  not	  visible	  in	  the	  graph.	  	  Activated	  macrophages	  produce	  Nitric	  Oxide	  by	  metabolizing	  arginine	  to	  citrulline.	  	  Metabolomic	  analysis	  was	  performed	  by	  Human	  Metabolome	  Technologies	  (HMT)	  using	  Capillary	  Electrophoresis	  Time-­‐of-­‐Flight	  Mass	  Spectrometry.	  	  All	  metabolomic	  analysis	  was	  done	  with	  an	  n	  =	  4.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01.	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Figure	  12.	  Pentose	  Phosphate	  Pathway	  metabolism	  in	  M3+	  and	  M3—	  cells.	  	  (A)	  Relative	  area	  of	  intra-­‐cellular	  Ribose-­‐5-­‐Phosphate	  (R5P),	  Ribulose-­‐5-­‐Phosphate	  (Ru5P),	  and	  Phosphoribosyl	  Pyrophosphate	  (PRPP).	  	  The	  pentose	  phosphate	  pathway	  provides	  intermediates	  for	  growth.	  	  Metabolomic	  analysis	  was	  performed	  by	  Human	  Metabolome	  Technologies	  (HMT)	  using	  Capillary	  Electrophoresis	  Time-­‐of-­‐Flight	  Mass	  Spectrometry.	  	  All	  metabolomic	  analysis	  was	  done	  with	  an	  n	  =	  4.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel	  	  	  *	  =	  p	  <	  0.05	  	  	  	  	  **	  =	  p	  <	  0.01	  	  	  	  	  ***	  =	  p	  <	  0.001	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Figure	  13.	  Proliferation	  of	  M3+	  and	  M3—	  cells	  in-­‐vitro.	  	  (A)	  In-­‐vitro	  proliferation	  over	  2	  days	  of	  M3+	  and	  M3—	  cells	  seeded	  at	  15,000	  cells/well	  using	  an	  bioluminescent	  ATP	  assay	  (photons	  /	  second).	  (B)	  In-­‐vitro	  proliferation	  over	  5	  days	  of	  M3+	  and	  M3—	  cells	  seeded	  at	  5,000	  cell/well	  using	  a	  BCA	  protein	  assay.	  n=8	  for	  both	  ATP	  and	  protein	  assays.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	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Figure	  14.	  Primary	  tumor	  weights	  of	  inoculated	  M3+	  and	  M3—	  cells	  in	  VM-­‐
mice.	  	  (A)	  In-­‐vivo	  Experiment	  I	  -­‐	  Primary	  tumor	  wet	  weight	  of	  1.5	  million	  M3+	  and	  M3—	  cells	  injected	  subcutaneously	  in	  the	  back	  of	  three	  VM	  mice.	  	  	  (B)	  In-­‐vivo	  experiment	  II	  -­‐	  Primary	  tumor	  wet	  weight	  of	  1.5	  million	  M3+	  and	  M3—	  cells	  injected	  subcutaneously	  in	  the	  flank	  of	  three	  VM	  mice.	  	  n=3	  mice	  for	  both	  experiment	  I	  and	  II	  and	  n=3	  for	  both	  M3+	  and	  M3—.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  	  	  *	  =	  p	  <	  0.05	  	  	  	  	  	  	  **	  =	  p	  <	  0.01.	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Figure	  15.	  The	  VM	  mouse	  metastatic	  tumor	  model.	  	  (A)	  Tumors	  were	  implanted	  subcutaneously	  with	  VM-­‐M3	  cells	  and	  dorsal	  images	  were	  taken	  over	  23	  days.	  (B)	  Appearance	  of	  metastatic	  nodules	  in	  liver	  at	  23	  days	  in	  mice	  implanted	  subcutaneously	  with	  VM-­‐M3	  cells	  (first	  panel)	  compared	  to	  a	  normal	  control	  liver.	  	  Images	  were	  taken	  from:	  	  L.	  C.	  Huysentruyt,	  P.	  Mukherjee,	  D.	  Banerjee,	  L.	  M.	  Shelton,	  T.	  N.	  Seyfried,	  Metastatic	  cancer	  cells	  with	  macrophage	  properties:	  evidence	  from	  a	  new	  murine	  tumor	  model.,	  Int.	  J.	  Cancer	  123,	  73–84	  (2008).	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Figure	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Figure	  16.	  In-­‐vitro	  luminescence	  output	  of	  M3+	  and	  M3—	  cells.	  	  ATP	  bioluminescence	  assay	  for	  luciferase	  activity	  in	  M3+	  and	  M3—	  cells	  in	  vitro	  using	  increasing	  concentrations	  of	  luciferin	  (substrate	  for	  luciferase).	  	  Progressive	  microgram	  amounts	  of	  luciferin	  were	  added	  to	  a	  120ul	  of	  growth	  media	  with	  30,000	  cells	  /	  well	  in	  a	  96-­‐well	  plate.	  	  The	  bioluminescence	  output	  is	  based	  on	  intracellular	  concentrations	  of	  ATP,	  oxygen,	  and	  luciferin	  as	  well	  as	  luciferase	  activity.	  	  The	  data	  was	  normalized	  to	  milligram	  protein	  levels.	  	  n=8	  in	  all	  conditions.	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	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Figure	  17.	  Assessment	  of	  metastatic	  spread	  in	  VM	  mice	  after	  inoculation	  with	  
M3+	  and	  M3-­‐	  cells.	  	  Visual	  assessment	  of	  metastasis	  nodules	  in	  liver	  and	  ATP	  (photons	  /	  sec)	  assessment	  of	  metastasis	  to	  brain	  in	  M3+	  and	  M3-­‐	  inoculated	  mice	  from	  experiment	  II.	  	  M3+	  and	  M3—	  cells	  are	  transfected	  with	  a	  firefly	  luciferase	  vector	  that	  emits	  light	  when	  in	  contact	  with	  luciferin,	  ATP,	  and	  oxygen.	  	  The	  brain	  was	  removed,	  incubated	  in	  a	  luciferin/PBS	  solution,	  and	  finally	  imaged	  for	  bioluminescence	  using	  a	  Xenogen	  IVIS	  Lumina	  system.	  	  The	  n=3	  for	  experiment	  II	  as	  is	  seen	  by	  noting	  mouse	  1,	  2,	  and	  3	  in	  the	  figure	  for	  both	  M3+	  and	  M3—	  conditions.	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Figure	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Figure	  18.	  Reduced	  oxygen	  consumption	  is	  associated	  with	  enhanced	  
metastasis	  in	  M3II+	  and	  M3II-­‐	  cells.	  	  (A)	  O2	  consumption	  measurement	  taken	  using	  a	  Presens	  Sensor	  Dish	  Reader	  (SDR)	  in	  an	  airtight	  Coy	  Laboratory	  Chamber.	  	  The	  percentage	  of	  gas	  was	  set	  at	  20%	  oxygen,	  5%	  CO2,	  and	  75%	  N2.	  	  The	  graph	  represents	  the	  percentage	  of	  O2	  consumed	  at	  48hrs	  relative	  to	  ATP	  levels	  also	  taken	  at	  48hrs	  (n=5).	  	  Error	  bars	  represent	  95%	  confidence	  intervals	  calculated	  using	  Excel.	  	  ***	  =	  p-­‐value	  <	  0.0001.	  	  (B)	  Two	  mice	  inoculated	  with	  7	  million	  M3II+	  or	  M3II—	  cell	  57	  days	  prior	  to	  date	  of	  taking	  the	  bioluminescence	  image.	  	  The	  image	  shows	  emission	  of	  photons	  from	  luciferase	  transfected	  M3II+	  and	  M3II—	  cells	  10	  minutes	  after	  injection	  of	  luciferin.	  	  The	  photons	  are	  made	  from	  the	  interaction	  of	  luciferin,	  ATP,	  and	  O2	  with	  luciferase.	  	  Purple	  to	  red	  indicates	  low	  to	  high	  cell	  concentration,	  respectively.	  	  n=1	  mouse	  for	  each	  MII3+	  /	  M3II—	  condition.	  	  A	  survival	  date	  was	  taken	  when	  each	  mouse	  became	  morbid.	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Introduction	  Mycoplasmas	   of	   the	   Mollicutes	   class	   are	   considered	   the	   smallest	   self-­‐replicating	  free-­‐living	   prokaryotes	   (1).	   	   Mycoplasma	   16S	   rRNA	   sequencing	   data	   used	   as	   a	  phylogenetic	   measure	   suggests	   that	   mycoplasmas	   originated	   from	   walled	   gram-­‐positive	   eubacteria	   by	   degenerative	   evolution	   roughly	   600	   million	   years	   ago	   (2).	  Unlike	   their	  walled	  ancestors,	   the	  Mollicutes	   (soft	   skin)	   class	   lacks	  a	   cell	  wall	   and	  thus	  is	  resistant	  to	  common	  bacterial	  cell	  wall	  targeted	  antibiotics	  such	  as	  penicillin.	  Mycoplasmas	  range	  in	  size	  from	  0.3µm	  to	  0.8µm,	  which	  in	  turn	  reflects	  their	  small	  genome	  sizes.	  	  	  M.	  genitalium	  has	  the	  smallest	  genome	  (580	  kb)	  of	  any	  organism	  that	  can	   be	   grown	   in	   pure	   culture	   and	   M.	   hyorhinis	   has	   the	   largest	   genome	   of	   the	  mycoplasmas	   (820	   kb)	   (3)	   (2)	   (4).	  With	   limited	   coding	   capacity,	   the	  mycoplasma	  genus	   has	   stringent	   nutritional	   requirements	   for	   fatty	   acids,	   sterols,	   some	   amino	  acids,	   nucleic	   acids,	   and	   various	   vitamins/cofactors	   (4)	   (5).	   	   Dependence	   on	  metabolic	  precursors	  for	  life	  leads	  to	  the	  need	  of	  extremely	  complex	  media	  in	  order	  to	  cultivate	  and	  therefore	  study	  mycoplasmas.	  	  However,	  high	  mycoplasma	  infection	  rates	  show	  that	  mycoplasmas	  propagate	  well	  within	  or	  attached	  to	  mammalian	  cells	  in-­‐vitro	  (6)	  (1).	  	  	  	  Mycoplasma	  infection	  of	  cultured	  mammalian	  cells	  can	   falsify	  many	  metabolic	  and	  non-­‐metabolic	  cellular	  assays	  including	  oxygen	  consumption	  assays	  (7),	  nitric	  oxide	  synthase	  activity	  (8),	  MTT	  viability	  assays	  (9),	  and	  mitochondrial	  protein	  synthesis	  determination	   (mycoplasma	   co-­‐purified	  with	   the	  mitochondrial	   fraction)	   (10).	   	   In	  agreement,	  M.	  hominis	  infection	  of	  HeLa	  cells	  significantly	  altered	  genetic	  expression	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profiles	   of	   1972	   genes	   (11).	   	   Another	   study	   found	   approximately	   200	   significant	  expression	   profile	   alterations	   in	   infected	  MCF7	   cells	   and	   70	   of	   those	   genes	   were	  involved	   in	   metabolism	   (12).	   In	   Mycoplasma	   pneumoniae-­‐infected	   individuals,	  tracheal	   cell	   explants	   were	   shown	   to	   have	   a	   decrease	   in	   ATP	   from	   respiration,	  possibly	   due	   to	   lower	   dehydrogenase	   activities	   of	   the	   cells	   (10).	   	   Similarly,	   M.	  hyorhinis	  is	  also	  capable	  of	  reducing	  the	  respiration	  system	  in	  heavily	  contaminated	  human	   skin	   fibroblast	   cells	   (13).	   	   Thus,	   mycoplasmas	   have	   a	   high	   potential	   for	  modulating	  host	  metabolism.	  	  	  
	  Regarding	  energy	  catabolism,	  mycoplasmas	  can	  be	  classified	  as	  fermentative	  or	  non-­‐fermentative	  (14).	  	  Fermentative	  mycoplasmas	  are	  able	  to	  gain	  energy	  by	  substrate-­‐level	  phosphorylation	  of	  ADP	  by	  glycolysis,	  specifically	  by	  the	  Embden-­‐Meyerhof-­‐Parnas	  (EMP)	  Pathway	  (14).	  	  Fermentation	  produces	  acid	  and	  occurs	  not	  to	  specifically	  make	  energy,	  but	  rather	  to	  oxidize	  NADH	  to	  allow	  glycolysis	  to	  continue	  to	  make	  energy	  (NAD+	  is	  required	  for	  the	  6th	  step	  of	  glycolysis)	  (15).	  	  	  Therefore,	  fermentative	  mycoplasmas	  are	  acidifiers	  and	  thus	  reducers	  of	  their	  environment.	  Some	  fermentative	  mycoplasmas	  such	  as	  M.	  
gallisepticum	  have	  the	  ability	  to	  carry	  out	  a	  non-­‐fermentative	  catabolism	  (16)	  (17)	  but	  viability	  and	  growth	  during	  a	  non-­‐fermentative	  catabolism	  are	  unclear.	  	  	  However	  in	  the	  presence	  of	  glucose,	  fermentative	  mycoplasmas	  produce	  a	  net	  waste	  of	  
acid.	  In	  contrast,	  non-­‐fermentative	  mycoplasmas	  do	  not	  produce	  a	  net	  waste	  of	  acid	  or	  alcohol,	  which	  indicates	  that	  their	  energy	  catabolism	  is	  mainly	  oxidative.	  In	  part,	  the	  oxidative	  catabolism	  of	  the	  non-­‐fermentative	  mycoplasmas	  is	  perhaps	  due	  to	  the	  lack	  of	  
